EUDA
NATIONAL FOCAL POINT

Research workbook

2026

FRANCE

Contributors

Valérie Ulrich, Isabelle Michot (OFDT)

2026 National report (2025 data) to the EUDA by the French Reitox National Focal Point
Supervision: Antoine Devémy

Contribution to the workbooks
2. *Legal framework*: Inès Delétang, Clara Moncel
3. *Drugs*: Olivier Le Nézet, Clément Gérome, Cindy Feng, Eric Janssen
4. *Prevention*: Carine Mutatayi
5. *Treatment*: Sophie Véron, Cindy Feng
6. *Best practice*: Valérie Ulrich, Carine Mutatayi
7. *Harms and Harm Reduction*: Cindy Feng, Sophie Véron, Eric Janssen
8. *Drug market and crime*: Yasmine Salhi
9. *Prison*: Lucas Bérard, Inès Delétang, Clara Moncel, Cindy Feng, Sophie Veron
10. *Research*: Valérie Ulrich, Isabelle Michot

With contributions of the project managers of the Interministerial Mission for Combating Drugs and Addictive Behaviours, MILDECA

Proofreading: Valérie Ulrich, Stanislas Spilka
Proofreading (English version): Anne de l'Eprevier, Eric Janssen, Ivana Obradovic
Bibliographic and legal references: Isabelle Michot

Table of contents

T0. Summary 3
T1. Drug-related research 4
T2. Trends (Not applicable for this workbook) 8
T3. New developments 9
T4. Additional information 31
T5. Sources and methodology 31

T0. Summary

Please provide an abstract of this workbook (target: 500 words) under the following headings: National profile
In this section please summarise the most relevant information included in the following sections, namely:

- A description of national profiles:
    - main entities financing research on drugs;
    - main research institutions involved in the research on drugs;
    - if applicable, the role of the national drug observatory in the implementation, execution or coordination of drug-related research activities;
    - main national or regional scientific journals publishing drug related research and
    - main drug-related research projects, (planned or ongoing)
- A description of research priorities (if available)
    - drug-related priorities defined in national/regional drug policy;
    - the role of drug-related research in national drug policy documents;
    - new topics emerging in drug-related research in your country (either in governmental or non-governmental research)

National profile

In France, the Ministry of National Higher Education, Research and Innovation (MENESR) designs, coordinates and implements national policy on research and innovation. Two primary academic organisations, the National Centre for Scientific Research (CNRS) and the National Institute for Health and Medical Research (INSERM), cover a wide range of research areas, from neurosciences, through public health and clinical research to social sciences.

The French National Focal Point (OFDT) is the main body involved in drug-related data collection, studies and network development. It collaborates extensively with national and European drug-related research teams. Dissemination of data and research results are also part of its mandate, together with publishing in national and international scientific journals, and promoting the use of research results in practice and policymaking.

The Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA) is the central structure close to the Prime Minister responsible for coordinating governmental action in the drugs field. Part of its role is to promote and fund drug-related research. Through its interministerial position and its collaboration with the OFDT and other partners, MILDECA plays a major role in the transfer of knowledge to decision-makers, professionals and citizens in France. MILDECA uses its own appropriations (Finance Act/drugs fund) to support research of a particularly strategic nature for steering public policies on drugs and addictive behaviour

New development

On 9 March 2023, the Government adopted its new Interministerial Strategy for Mobilisation against Addictive Behaviours (SIMCA) to be deployed over 4 years (2023-2027) (MILDECA 2023).

In line with previous government plans, the development of observation and research on addictions constitutes one of the 10 strategic areas retained in this strategy. The public authorities are reaffirming their desire to base public action on solid knowledge. They are committed to supporting and directing the production of scientific data, which can easily be used by the public authorities.

Government guidelines aim to 1/ consolidate observation systems, 2/ continue to structure research and 3/ promote the evaluation of systems and policies.

Among the research priorities, the strategy stresses the importance of clinical research aimed at developing effective drug treatments, in particular with regard to addictions for which there are no substitute products (cocaine).

At the same time, particular attention is paid to the development of research on the illicit supply of narcotics.

The public authorities also underline their desire to promote evaluative research on subjects that have received little attention such as the quality, effectiveness and efficiency of health and medico-social care as well as penal responses to the use of psychoactive products.

T1. Drug-related research[1]

The purpose of this section is to

- Describe the organization of drug-related research in your country
- Provide a summary of specific resources on drug-related research available in your country
- Update the available information already provided to the EMCDDA (workbook will be pre-filled).

T1.1. Please update the main drug-related research institutions/associations/bodies (public or private) in your country. Please provide links, also to pages in English, if available.

- Centre National de la Recherche Scientifique (CNRS): http://www.cnrs.fr/index.php
- Conservatoire National des Arts et Métiers (CNAM): https://www.cnam.fr/site-fr/
- École des Hautes Études en Santé Publique (EHESP): http://www.ehesp.fr
- École des Hautes Études en Sciences Sociales (EHESS): https://www.ehess.fr
- France Universités: https://franceuniversites.fr/en/
- Fédération Nationale des Observatoires Régionaux de la Santé (FNORS): http://www.fnors.org/index.html
- Fondation Nationale des Sciences Politiques (FNSP): https://www.sciencespo.fr/fr/
- Institut de Recherche pour le Développement (IRD): https://www.ird.fr/
- Institut National de Recherche pour l'agriculture, l'alimentation et l'environnement (INRAE): https://www.inrae.fr
- Institut National de la Santé et de la Recherche Médicale (INSERM): https://www.inserm.fr
- Observatoire Français des Drogues et des Tendances addictives (OFDT): https://www.ofdt.fr/
- Santé publique France (SpF): https://www.santepubliquefrance.fr/
- Drogues, sciences sociales et sociétés, Un programme EHESS/INSERM avec le soutien de l'IReSP: https://drogueshs.hypotheses.org/

T1.2. Please update the main institutions/associations/bodies/programmes (public or private) funding drug-related research in your country.
Please provide links, also to pages in English, if available.

- The Fund for Combating Addiction (FLCA) is the main funding source for research on drugs and addictive behaviours in France. It was created within the *Caisse Nationale de l'Assurance Maladie* [National Health Insurance Fund] by the law no. 2021-1754 of 23 December 2021 on the financing of social security for 2022. It succeeds the "fonds de lutte contre les addictions liées aux substances psychoactives" [Fund for Combatting Addiction to psychoactive substances] (set up in 2019 by law no. 2018-1203 of 22 December 2018), which itself replaced the "fonds de lutte contre le tabac" [Fund for Combatting Tobacco] (set up in 2017 by decree no. 2016-1671 of 5 December 2016). This modified, among other things, the volume and distribution of resources dedicated to research, with a substantial annual sum earmarked to "support knowledge sharing, innovation, applied research and the evaluation of prevention and care actions".
- The Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA: http://www.drogues.gouv.fr/) is the central structure responsible to the Prime Minister for coordinating governmental action in the drugs field. Part of his role is to promote and fund drug related research. The 2023-2027 Interministerial Strategy for Mobilisation against Addictive Behaviours (SIMCA) provides for the continued structuring of research in the field of addictions, including behavioural addictions, notably gambling. Furthermore, to reinforce the fight against drugs, particular attention is paid to the development of research on the illicit supply of drugs through the design and management of an Interministerial Applied Research Programme to Combat Drugs (PIRALAD). Finally, treating addictions to certain substances, for which no medicinal treatment currently exists, requires significant investment in clinical research in order to develop new, effective therapies. Research prospects in the fight against drugs and addictions are also set out in the annex (entitled "*Politique de lutte contre les drogues et les conduites addictives*") to the 2026 Finance Bill (transversal policy document annex to the Finance Bill for 2026, policy to combat drugs and addictive behaviours). The avenues proposed include reviewing calls for projects focused on mental health and addiction, in the context of recognising mental health as a major national cause; supporting multidisciplinary, evaluative and interventional research units, with particular emphasis on participatory approaches in the humanities and social sciences so as to reflect the environments in which the studied populations live; and identifying susceptibility factors for addiction, with a particular focus on behavioural addictions.
- The Ministry of Higher Education, Research and Innovation (MESRI: https://www.enseignementsup-recherche.gouv.fr/) designs, coordinates and implements national policy on research and innovation. A large scope of research areas ranging from neurosciences, through public health and clinical research to social sciences is mainly covered by two major academic operators: the National Centre for Scientific Research (CNRS) and the National Institute for Health and Medical Research (INSERM).
- The French Research Agency (*Agence Nationale de la Recherche* – ANR: http://www.agence-nationale-recherche.fr/en/project-based-funding-to-advance-french-research/) is in charge of programming national research and innovation. The agency establishes the thematic priorities of research and allocates the resources. Every year, the agency launches calls for tenders covering a large spectrum of scientific areas.

- The Ministry of Labour, Health, Solidarity and the Family (https://sante.gouv.fr/) *"Programme Hospitalier de Recherche Clinique"* - PHRC). It also funds studies on specific populations of drug users, interventions (prevention, treatment, harm reduction) or legal disposition
- The National Research Agency on AIDS (*Agence Nationale de Recherche sur le Sida*https://www.anrs.fr/*Santé publique France*: https://www.santepubliquefrance.fr/) implement regular surveys and research projects, notably on the links between injecting drug use and infectious diseases (mainly HIV and HCV). Under the supervision of the MESRI (Ministry of Higher Education, Research and Innovation) and the MSP (Ministry of Health and Prevention), the ANRS also brings together an inter-institutional network of national and international doctors and researchers, patient associations and representatives of civil society, working together to define and implement projects. SPF's research and expertise work on addictions is carried out within the framework of two units of the agency, one being dedicated to infectious diseases and the other devoted to prevention and health promotion.
- The French National Cancer Institute (http://en.e-cancer.fr/) is the preeminent health and science agency in charge of cancer control in France, created in 2004. It reports to the ministries for Health and for Research. About half of its budget (€100 million) is allocated to research funding. Each year, the Institute organises more than fifteen competitive calls for proposals in the areas of research, public health, cancer care organisation and patient information.
- The Institute for Public Health Research (*Institut de Recherche en Santé Publique* GIS-IreSP, http://www.iresp.net/) helps support and facilitate research into psychoactive substance use and addiction through a funding mechanism composed of calls for research proposals, calls for applications for PhD grants, calls for support actions. It is financed by the Fund for Combating Addiction.
- Regional health agencies (*Agences regionals de santé* - ARS) implement national health policy at local level. The regional roadmaps drawn up for this purpose may include budgets for addiction research projects.
- NGOs and foundations (such as the *Fondation de France*) representing practitioners, users and companies (alcohol suppliers, tobacco industry and pharmaceutical laboratories) also regularly fund surveys and research project in these areas.

T1.3. Please update the list of the main national scientific journals where drug-related research is published in your country. Please provide links, also to pages in English, if available.

Name	Topic	Language	Abstract
Actualités pharmaceutiques https://www.em-consulte.com/revue/ACTPHA	Treatment	French	English
Addiction(s) : recherches et pratiques https://www.federationaddiction.fr/publications/revue/	Treatment	French	French
Adolescence https://shs.cairn.info/revue-adolescence?lang=fr	Psychology	French	English
Agora débats/jeunesses https://shs.cairn.info/revue-agora-debats-jeunesses?lang=fr https://shs.cairn.info/journal-agora-debats-jeunesses?lang=en	Multidisciplinary	French	English

Name	Topic	Language	Abstract
Alcoologie et Addictologie https://sfalcoologie.fr/revue/	Treatment	French, English	English
Annales Médico-psychologiques, revue psychiatrique https://www.sciencedirect.com/journal/annales-medico-psychologiques-revue-psychiatrique	Psychiatry	French, English	English
Bulletin de l'Académie Nationale de Médecine https://www.sciencedirect.com/journal/bulletin-de-lacademie-nationale-de-medecine	Public health	French	English
Bulletin Épidémiologique Hebdomadaire https://www.santepubliquefrance.fr/revues/beh/bulletin-epidemiologique-hebdomadaire	Epidemiology and public health	French	English
Cahiers de la Sécurité et de la Justice https://www.ihemi.fr/publications/les-cahiers-de-la-securite-et-de-la-justice	Sociology and political science	French	English
Le Courrier des Addictions https://www.edimark.fr/revues/le-courrier-des-addictions	Addiction all topics	French	English
Déviance et Société https://shs.cairn.info/revue-deviance-et-societe https://shs.cairn.info/journal-deviance-et-societe?lang=en	Sociology and political science	French	English
EchoGéo https://journals.openedition.org/echogeo/	Geopolitics	French	English
L'Encéphale https://www.sciencedirect.com/journal/lencephale	Treatment	French, English	English
L'Information Psychiatrique https://www.jle.com/en/revues/ipe/revue.phtml	Treatment	French, English	English
Médecine des Maladies Métaboliques https://www.sciencedirect.com/journal/medecine-des-maladies-metaboliques	Medicine	French	English
Médecine/Sciences https://www.medecinesciences.org/fr/ https://www.medecinesciences.org/en/	Medicine	French	English
Neuropsychiatrie de l'Enfance et de l'Adolescence https://www.sciencedirect.com/journal/neuropsychiatrie-de-lenfance-et-de-ladolescence	Psychiatry	French, English	English
Politix, revue des sciences sociales du politique https://shs.cairn.info/revue-politix?lang=fr	Human and social sciences	French	English
La Presse Médicale https://www.sciencedirect.com/journal/la-presse-medicale	Health	French, English	English
Psychotropes, Revue internationale des toxicomanies et des addictions https://stm.cairn.info/revue-psychotropes?lang=fr https://stm.cairn.info/journal-psychotropes?lang=en	Treatment	French	English

Name	Topic	Language	Abstract
Revue des Maladies Respiratoires https://www.sciencedirect.com/journal/revue-des-maladies-respiratoires	Medicine	French	English
Revue Française des Affaires Sociales https://shs.cairn.info/revue-francaise-des-affaires-sociales?lang=fr https://shs.cairn.info/journal-revue-francaise-des-affaires-sociales?lang=en	Human and social sciences	French	English
Revue Française de Sociologie https://shs.cairn.info/revue-francaise-de-sociologie?lang=fr https://shs.cairn.info/journal-revue-francaise-de-sociologie?lang=en	Sociology	French	English
La Revue de médecine interne https://www.em-consulte.com/produit/revmed	Medical Sciences	French, English	English
La Revue du Praticien - Monographie https://www.larevuedupraticien.fr/numeros	Medical Sciences	French	English
Rhizome https://orspere-samdarra.com/publications/rhizome/	Mental health and precariousness	French	French
Santé Mentale https://www.santementale.fr/la-revue/	Mental health	French	French
Santé Publique https://stm.cairn.info/revue-sante-publique?lang=fr https://stm.cairn.info/journal-sante-publique?lang=en	Epidemiology and public health	French	English
Sciences Sociales et Santé https://stm.cairn.info/revue-sciences-sociales-et-sante?lang=fr https://shs.cairn.info/journal-sciences-sociales-et-sante?lang=en	Human and social sciences	French, English	English
Sécurité globale https://shs.cairn.info/revue-securite-globale?lang=fr	Sociology and political science	French	French
Sociologie https://shs.cairn.info/revue-sociologie?lang=fr	Sociology	French	English
Soins Psychiatrie https://www.em-consulte.com/revue/SPSY/presentation/soins-psychiatrie	Psychiatry	French	English
Therapies https://www.sciencedirect.com/journal/therapies	Treatment	French, English	English
Toxicologie Analytique et Clinique https://www.sciencedirect.com/journal/toxicologie-analytique-et-clinique	Toxicology	French, English	English

T1.4. Please update the list of drug-related research relevant websites/resources you would like us to include in your research country profile. Provide links, also to pages in English, if available.

T2. Trends (Not applicable for this workbook)

T3. New developments

The purpose of this section is to provide information on any notable or topical developments observed in drug-related research in your country **since your last report**.
T1 is used to establish the baseline of the topic in your country. Please focus on any new developments here. If information on recent notable developments have been included as part of the baseline information for your country, please make reference to that section here. It is not necessary to repeat the information.

T3.1. Please update the list of the main drug-related, recent/on-going since your last report studies/research projects in your country. Please provide links, also to pages in English, if available.
If possible, classify each study/research project under one of the following categories:
(1) Basic biological, neurobiological and behavioural research (including aetiological and addictive behaviour research);
(2) Population based and clinical epidemiology (including site surveys, ethnographic studies and acute toxicity studies);
(3) Demand reduction (including prevention, treatment, harm reduction, reintegration and clinical treatment research);
(4) Supply, supply reduction and crime;
(5) Drug policy (including laws, economic issues and strategies);
(6) Other topics.

If it is not possible to identify the main drug-related on-going studies/research projects in your country, please provide a list of the most relevant current bibliographic references.

Since 2022, the scope of public research funding has been extended to so-called substance-free addictions (screens, gambling and video games) by Article 84 of Law no. 2021-1754 of 23 December 2021 relating to the Social Security financing for 2022. This expansion aims to respond to the concerning reports of problematic uses observed in recent years, mainly among adolescents and young adults.

The information currently collated concerning the efforts devoted to research is set out below.

In 2025, the FLCA financed 59 research projects supported by INCa (National Cancer Institute) and IReSP (Institute for Public Health Research) in many disciplines (neurosciences, epidemiology, public health, economics, social sciences, etc.) for an amount of €12.4 million. Of these 59 projects, 14 require a preliminary study or the prior structuring of a research partnership. This is in addition to funding for 17 doctoral students and support for 5 early-career researchers and 2 research networks.

Projects funded in 2025 included five projects on cocaine, one targeting striatal cholesterol metabolism to combat cocaine addiction and another focusing on studying the interactions between the insular cortex and the dopaminergic system (protective mechanisms of progesterone against cocaine relapse). Three research projects focused on opioids and one study addressed nitrous oxide.

In addition, the French Institute for Public Health Research (IReSP) organised webinars in 2025 on facilitating the therapeutic relationship in addiction medicine through digital technology, as well as on the impact of screens on children's development and physical and mental health.

In 2025, the French Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA) funded two research projects for a total of €350 000:

- a victimisation survey on violence associated with psychoactive substances;
- the third part of a survey focusing on wastewater analysis.

In 2025, MILDECA also launched a call for research proposals on the illicit supply and trafficking of drugs as part of the PIRALAD programme (Interministerial Applied Research Programme to Combat Drugs) with a 2025 budget of €539 400. This programme funded 4 new research projects in 2025.

- **EVOTRAF: long-term trends in narcotic substances seized in France**. The aims are to exploit the national Standardised Narcotics Processing System (STUPS) database, using the latest data analysis approaches to monitor and detect trends and disruptions in the market for illicit narcotic substances. The project leads are: the National Forensic Science Institute (SNPS), the Institute of Analytical Sciences (ISA), and Institut Agro Dijon, in collaboration with the French Monitoring Centre for Drugs and Drug Addiction (OFDT);
- **ORIGINSTUP 2: determining the geographical origin of cocaine samples seized in France – study of the evolution of routes from production to sale.** The aims are to explore the use of scientific methods to determine the geographical origin of the production of seized cocaine samples and their application in France. The project leads are: the Forensic Sciences Institute of the French Gendarmerie (FSIFG) and the Institute of Analytical Sciences (ISA);
- **PRESYNTH: illegal synthetic drugs in Europe and Latin America.** The aims are to provide a study of national regulations relating to chemical precursors in Latin America and Europe, and a study of practices linked to the online purchase and sale of synthetic drugs in both regions. The project leads are the Centro Latinoamericano-Suizo (CLS-HSG), the University of St. Gallen and the University of Lille;
- **DRAME: drugs and murders – analyses in Marseille and its surrounding area.** The aims are to analyse lethal violence linked to local drug trafficking sites, its interdependence with police and judicial work, its impacts on neighbourhoods as well as on victims' families and those around them, its repercussions on the prison system, and to conduct an analysis of images in the press, public discourse, and fiction. The project lead is the French National Centre for Scientific Research (CNRS).

It should be noted that in 2025, the OFDT, in partnership with MILDECA, published a study funded by PIRALAD in 2024 on changes in illicit drug markets in mainland France, in terms of both volume and value (Ben Lakhdar and Massin 2025). This research, conducted by Professors Christian Ben Lakhdar and Sophie Massin from the University of Lille, estimates the average total turnover at €6.8 billion in 2023, nearly three times higher than in 2010, mainly driven by the expansion of the psychostimulant market (cocaine and synthetic stimulants).

Furthermore, following joint funding from the MILDECA and the Ministry of Health in 2024, the French National Institute for Health and Medical Research (INSERM) conducted in 2025 and published in early 2026 a collective expert report providing an updated and contextualised overview of cocaine use in France (INSERM 2026). This expert report identifies the most effective or promising strategies and measures in the fields of prevention, harm reduction, health care and medico-social support for individuals who use and/or suffer from use-related disorders, in addition to public health policies.

In total, 18 projects were funded under the PIRALAD programme between 2022 and 2025 for a total of €1.8 million.

Moreover, in March 2025, the MILDECA organised and funded together with the Urban School of Sciences Po, a second series of unprecedented conferences on the illicit supply of narcotics and its urban challenges.

Under the Investments for the Future programmes (PIA), an addiction component is included in several cohort projects. For example, the I-Share cohort (Internet-based Students Health Research Enterprise) examines risk behaviours, including addiction and substance misuse, among 30 000 students.

The OptoPath™ project combines the expertise of neurobiologists, electrophysiologists and experimental psychologists to identify new therapeutic targets for four major psychological disorders: addictions, obesity, post-traumatic stress syndrome/anxiety disorders and memory deficits.

The Bio-Psy Labex (Biology for Psychiatry) brings together psychiatrists, neuroscientists and geneticists with the common aim of understanding the biological mechanisms involved in psychiatric disorders, including addictions, in order to improve their diagnosis and treatment.

Since its creation in 2019, the FLCA has funded specific OFDT research projects. All of these projects are taking place over several years. The following studies were completed in 2025:

- CIPPAL-ADAM (International Comparison of Public Policies for Controlling the Attractiveness and Accessibility of Alcohol) is a documentary, qualitative and quantitative online survey aiming to compare, for six countries including France, the various national regulations governing alcohol marketing and advertising via audiovisual media and the Internet, and their influence on awareness and exposure among adolescents and young adults to marketing channels (see https://en.ofdt.fr/en/cippal-survey-2075).
- OUDOM (Observations of drug use in the French overseas departments and territories), aiming to 1/ deploy the OFDT's SINTES network in collaboration with actors in the field and laboratories and 2/ conduct qualitative fieldwork on the use and supply of illicit psychoactive substances.

The studies continuing in 2025 are:

- PSPJ (*Sports betting and problematic behaviours among young people*), a qualitative study aimed at better understanding the intrinsic factors and motivations and the environmental incentives for sports betting practices among young adults and adolescents (minors) in France, in light of the trajectories and strategies of engagement in gambling.
- ACCES 2025 (*Representative analysis of the profiles and care pathways of CAARUD users*) aiming to deploy a nationally-representative quantitative survey system among CAARUD users to analyse usage practices and clinical profiles of users.
- VIXAL (*Sexual violence and alcohol consumption*), survey on the links between alcohol consumption and sexual violence using a mixed-methods approach.
- EROPP 2026 (*Survey on representations, opinions and perceptions regarding psychoactive drugs),* enabling the regular production of estimates of levels of drug use and gambling practices and to monitor their trends.
- ESSPRI 3 (*Survey on health and substances in prison)* for the assessment of consumption among detainees in order to provide regular prevalence data on the use of psychoactive substances in detention among adult male and female prisoners incarcerated in France.
- TREND/SINTES (*Structuring and strengthening of the Emerging Trends and New Drugs-TREND/National Identification System for Toxics and Substances-SINTES scheme)* contributing to health monitoring at national and European level.

On 27 November 2025, the OFDT organised a research symposium to mark the 25th anniversary of its TREND and SINTES schemes. This symposium provided an opportunity to highlight the originality of both schemes, their methodology, the data they produce, and their contribution to public health monitoring for local and national health stakeholders. A recording of the symposium is available on the OFDT website: https://www.ofdt.fr/evenement/colloque-25-ans-de-trend-et-sintes-2528.

The total number of scientific publications on addiction published in 2025 up to the first quarter of 2026 equals 287, of which:

- Publications on addiction/addictology: 42
- Publications on cannabis: 45
- Publications on chemsex: 12
- Publications on cocaine/crack cocaine: 37
- Publications on opioids: 17
- Publications on NPS : 28
- Publications on nitrous oxide: 7
- Publications on several products: 90
- Publications on other substances: 9

Bibliography 2025-1st quarter 2026

(1) Basic biological, neurobiological and behavioural research (including aetiological and addictive behaviour research) = 46 articles

Adebo, M., Bonnet, M., Laouej, O., Defaix, C., McGowan, J.C., Butlen-Ducuing, F. *et al.* (2025) Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms. Fundam Clin Pharmacol 39 (4) e70038, 10.1111/fcp.70038.

Ait Tayeb, A.E.K., Laforgue, E.J., Schreck, B., Grall-Bronnec, M., Hardouin, J.B., Leboucher, J. *et al.* (2025) ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder. Fundam Clin Pharmacol 39 (3) e70013, 10.1111/fcp.70013.

Allache, A., Auriacombe, M., Alexandre, J.M. and Serre, F. (2026) Craving as a transdiagnostic marker of addiction? A perspective for behavioral addictions. Front Behav Neurosci 20 1770895, 10.3389/fnbeh.2026.1770895.

Amrouche, L. (2025). Opioïdes de synthèse, la course à la puissance [Synthetic opioids, the race for power] (with English abstract). Actualités Pharmaceutiques 64 (646) 37-39, 10.1016/j.actpha.2025.03.010.

Angerville, B. (2026). Cocaïne et interactions médicamenteuses [Cocaine and drug interactions] (with English abstract). Le Courrier des Addictions 28 (1) 25-27.

Arnoux, I., Capano, A., Yakoubi, R., Boulogne, C., Ezan, P., Escartin, C. *et al.* (2025) Inhibiting the JAK-STAT3 pathway in nucleus accumbens astrocytes alleviates cocaine-induced motor hyperactivity. Prog Neurobiol 255 102852, 10.1016/j.pneurobio.2025.102852.

Audi, D., Hajeer, S., Saab, M.B., Saab, L., Harati, H., Desoutter, A. *et al.* (2025). Effects of cannabis use on neurocognition: A scoping review of MRI studies. Journal of Psychoactive Drugs 57 (4) 357-373, 10.1080/02791072.2024.2372377.

Barillot, L., Chauvet, C., Chauchard, E., Besnier, M., Harika-Germaneau, G., Noël, X. *et al.* (2025) Moving beyond animal models: enriched environments and human substance use disorders. Front Behav Neurosci 19 1629918, 10.3389/fnbeh.2025.1629918.

Bendjilali-Sabiani, J.J., Eiden, C., Lossois, M., Martrille, L., Peyriere, H. and Mathieu, O. (2026) Postmortem distribution of isotonitazene and its three metabolites in the first lethal case observed in France. Forensic Science International 379 112763, 10.1016/j.forsciint.2025.112763.

Boulin, F., Bédat-Millet, A.L., Didier-Laurent, A., Louillet, F., Quesney, G., Hébant, B. *et al.* (2025). Neurological damage from recreational nitrous oxide use: Two distinct electroclinical profiles in a retrospective cohort. Revue Neurologique 181 (8) 742-747, 10.1016/j.neurol.2025.07.002.

Carbone, M.G., Maremmani, I., Della Rocca, F., Gastaldello, G., Mazzetto, L., Bellini, A. *et al.* (2026) From Neuroadaptation to Neuroprogression: Rethinking Chronic Cocaine Exposure Through a Model of Cocaine-Related Cerebropathy. J Clin Med 15 (6) 2222, 10.3390/jcm15062222.

Cavalli, M., Ezaru, A., Olivero, A., Sacconi, S., Negrila, A., Puma, A. *et al.* (2025). Nitrous Oxide-Associated Myelopolyneuropathy-A Case Series. J Clin Neuromuscul Dis 27 (1) 1-8, 10.1097/cnd.0000000000000498.

Contarino, A. (2025) Genetic inactivation of the CRF(2) receptor eliminates morphine-induced sociability deficits in female mice. Neuropharmacology 274 110480, 10.1016/j.neuropharm.2025.110480.

Cupertino, R.B., Medland, S.E., Ottino-Gonzalez, J., Cao, Z., Juliano, A., Pancholi, D. *et al.* (2025). Impulsivity behaviors and white matter mediate the relationship between genetic risk for cannabis use disorder and early cannabis use in adolescents. Addiction 120 (5) 984-996, 10.1111/add.16750.

Diringer, M., Bruggeman, M. and Lutz, P.E. (2026) The DNA methylation enzymatic machinery in substance use disorders: A systematic review. Neurobiol Dis 218 107241, 10.1016/j.nbd.2025.107241.

Frajerman, A., Marzo, A., Chaumette, B., Jay, T.M., Demars, F., Lamazière, A. *et al.* (2025) Lifelong dietary Omega-3, -6, and -9 ratios shape adult behavior and response to adolescent THC exposure in rats. Pharmacol Biochem Behav 256 174086, 10.1016/j.pbb.2025.174086.

Garcia, M. (2026). Addiction et responsabilisation (in French only). Revue Médecine et Philosophie (14) 64-72.

Gauld, C., Depannemaecker, D., Auriacombe, M. and Serre, F. (2025) Computational modeling of the temporal influences between cues, craving and use in addiction: a dynamical system analysis based on ecological momentary assessment data. Transl Psychiatry 15 (1) 419, 10.1038/s41398-025-03531-z.

Gish, A., Peyré, A., Richeval, C., Pleignet, E., Cottereau, V., Gaulier, J.M. *et al.* (2025). Elucidation of human metabolism of ADB-FUBIATA for population exposure assessment. Environ Sci Pollut Res Int 32 30871-30880, 10.1007/s11356-025-36571-5.

Gish, A., Radwan, E., Richeval, C., Protopopescu, C., Wiart, J.-F., Hakim, F. *et al.* (2026). Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four endocannabinoids and endocannabinoid-like substances in plasma: Application in an HIV-hepatitis C virus coinfected population. Therapeutic Drug Monitoring 48 (3) 379-386, 10.1097/ftd.0000000000001397.

Horstman, L.I., Koller, D., Cabana-Domínguez, J., Llonga, N., Icick, R., Vorspan, F. *et al.* (2026) Polygenic risk scores reveal genetic underpinnings of comorbidity between substance use disorders and ADHD. Eur Neuropsychopharmacol 107 112799, 10.1016/j.euroneuro.2026.112799.

Kondev, V., Godino, A., Kipp, B.T., Hennigan, E., Casey, C., Patel, V. *et al.* (2025) Dopamine receptor 1-expressing cells in the ventral hippocampus encode cocaine-context associations. Res Sq in press, 10.21203/rs.3.rs-8079719/v1.

Laflamme, G., Hamzeh-Cognasse, H., Cognasse, F. and Loubaki, L. (2026) Pilot study on cannabis-induced alterations in platelet function: implications for transfusion medicine. Platelets 37 (1) 2644368, 10.1080/09537104.2026.2644368.

Lara, M.K., Carrette, L.L.G., Sanches, T.M., Polesskaya, O., Avelar, A., Beeson, A. *et al.* (2025) Genome-wide association study of cocaine self-administration behavior in Heterogeneous Stock rats. bioRxiv in press, 10.1101/2025.07.17.660811.

Letort, K., Lageyre, L., Ahmed, S.H. and Guillem, K. (2026) Increased drug seeking and vulnerability to relapse after escalation of nicotine intake by dose manipulation in male and female rats. Psychopharmacology in press, 10.1007/s00213-025-06973-x.

Mariani, Y., Dalla-Tor, T., Garavaldi, T., Julio-Kalajzić, F., Gisquet, D., Gomez-Sotres, P. *et al.* (2025). Astroglial CB(1) Reveal Sex-Specific Synaptic Effects of Amphetamine. Glia 73 (8) 1673-1691, 10.1002/glia.70026.

Martín-Monteagudo, C., Sánchez Romero, J., Adams, J.M., Puente, N., Grandes, P., Marsicano, G. *et al.* (2025) An astrocytic ensemble at vHip-NAc synapses modulates cognitive impairments induced by chronic tetrahydrocannabinol exposure. Nat Commun 17 471, 10.1038/s41467-025-67166-w.

Mingarelli, V. (2026). Généalogie de l'intoxication et politique de l'accoutumance. Nietzsche, une pensée de l'addiction (in French only). Revue Médecine et Philosophie (14) 44-52.

Mongrédien, R., Anesio, A., Fernandes, G.J.D., Eagle, A.L., Maldera, S., Pham, C. *et al.* (2025). Astrocytes control cocaine-induced synaptic plasticity and reward through the matricellular protein hevin. Biological Psychiatry 98 (8) 612-623, https://www.sciencedirect.com/science/article/pii/S0006322325010728.

Monticelli, G., Nardi, A., Mezzelani, M., Bernardini, I., Dalla Rovere, G., El Idrissi, O. *et al.* (2025) Transcriptomic and microbiota responses in Mytilus galloprovincialis exposed to environmental concentrations of caffeine and cocaine. Aquatic Toxicology 286 107458, 10.1016/j.aquatox.2025.107458.

Nadal-Gratacós, N., Pain, S., Mata, S., Puigseslloses, P., De Macedo, M., Lardeux, V. *et al.* (2026) Pharmacological characterization of 4-F-3-Me-α-PVP: A novel synthetic cathinone with psychostimulant effects and abuse liability in rodents. J Psychopharmacol in press, 10.1177/02698811261430492.

Nakamura, Y., Labarchède, M., Mendes, T., Nakamura, Y., Longueville, S., Albertini, G. *et al.* (2025) Broad transcriptomic effects of Egr1 knockdown in the mouse nucleus accumbens core and its role in cocaine locomotor sensitization. Prog Neuropsychopharmacol Biol Psychiatry 144 111574, 10.1016/j.pnpbp.2025.111574.

Nikolic, M., Cox, S.M.L., Jaworska, N., Castellanos-Ryan, N., Dagher, A., Vitaro, F. *et al.* (2025). A multimodal neuroimaging study of youth at risk for substance use disorders: Functional magnetic resonance imaging and [(18)F]fallypride positron emission tomography. Alcohol, Clinical and Experimental Research 49 (2) 332-344, 10.1111/acer.15511.

Noble, F. (2025). Neurobiologie de l'addiction à la cocaïne (in French only). Santé Mentale n°301 62-66.

Nunthakitgoson, W., Kaewwan, N., Butcha, S., Ketkaew, M., Kuhn, A. and Wattanakit, C. (2026) Selective electrochemical detection of cannabidiol (CBD) and tetrahydrocannabinol (THC) at molecular-imprinted mesoporous Pt-Ir surfaces. Biosensors and Bioelectronics 292 118103, 10.1016/j.bios.2025.118103.

Pain, S., Nadal-Gratacós, N., De Macedo, M., Lardeux, V., Mata, S., Puigseslloses, P. *et al.* (2026) Neurochemical and behavioral evidence of high abuse liability of 3F-NEB, a novel synthetic cathinone. Eur J Pharmacol 1015 178570, 10.1016/j.ejphar.2026.178570.

Palhas, M., Corne, R. and Mongeau, R. (2025) Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction. Prog Neuropsychopharmacol Biol Psychiatry 142 111533, 10.1016/j.pnpbp.2025.111533.

Pelletier, R., Nahle, D., Sarr, M., Bourdais, A., Morel, I., Le Daré, B. *et al.* (2025). Identifying metabolites of new psychoactive substances using in silico prediction tools. Arch Toxicol 99 (7) 2953-2973, 10.1007/s00204-025-04049-5.

Pesthy, Z.V., Berta, K., Vékony, T., Farkas, B.C., Németh, D. and Kun, B. (2026) Dissociating the cognitive underpinnings of recreational cannabis use from problematic use. Compr Psychiatry 147 152685, 10.1016/j.comppsych.2026.152685.

Ramborger, J., Mosquera, J., Brennan, M., Sichel, B., Othman, D., Plasil, S. *et al.* (2026). Incentive salience, not psychomotor sensitization or tolerance, drives escalation of cocaine self-administration in heterogeneous stock rats. Neuropsychopharmacology 51 1176-1187, 10.1038/s41386-026-02350-0.

Schiestel, T., Magny, R., Rollet, D., Houzé, P. and Labat, L. (2025). Misuse of cocaine in a patient with cluster headache: A clinico-biological case report. Annales de Biologie Clinique 83 (6) 696-699, 10.1684/abc.2025.2015.

Shi, R., Xiang, S., Alnæs, D., Chen, D., Chen, Z., Banaschewski, T. *et al.* (2025) Lifespan investigation of brain volumetric changes associated with substance use disorders. medRxiv in press, 10.1101/2025.05.28.25328476.

Sneddon, E.A., Chonwattanagul, S., Bai, K., Kurup, P.H., Plasil, S.L., Doyle, M.R. *et al.* (2026) High incidence of estrous cycle irregularities in heterogeneous stock (HS) rats is associated with footshock-resistant cocaine intake. Psychopharmacology (in press), 10.1007/s00213-026-07041-8.

Vecchiarelli, H.A., Baglot, S.L., Black, T., Choi, E.Y., Cupo, L., Sandberg, C. *et al.* (2026) Effects of prenatal cannabis exposure on offspring mental health: A focus on the role of the immune system. Neuroscience & Biobehavioral Reviews 181 106488, 10.1016/j.neubiorev.2025.106488.

Vielle, C., Vignal, L., Tiran-Cappello, A., Meffre, J., Maurice, N., Degoulet, M. *et al.* (2025) Presence of an unfamiliar peer reverses escalated cocaine intake in male rats: Involvement of the subthalamic nucleus. Prog Neuropsychopharmacol Biol Psychiatry 44 111588, 10.1016/j.pnpbp.2025.111588.

Voronkov, M., Nikonov, G., Uzbil, M., Milevich, G., Abernethy, J. and Barthélémy, I. (2025) Is Fentanyl Rebound an Intrinsic Feature of Naloxone Reversal? Pharmaceuticals 18 (11), 10.3390/ph18111634.

(2) Population based and clinical epidemiology (including site surveys, ethnographic studies and acute toxicity studies) = 119 articles

Abbas, Z., Lacroix, C., Jouve, E., Eiden, C., Micallef, J., Peyrière, H. *et al.* (2026) Use of psychoactive substances before incarceration among prison inmates with drug abuse or dependence: Data from the OPPIDUM program. Fundamental and Clinical Pharmacology 40 (1) e70058, 10.1111/fcp.70058.

Aboujaoude, M., Hamache, N., Dillinger, J.G., Trimaille, A., Bouleti, C., Delmas, C. *et al.* (2026) Prognostic Impact of Recreational Drug Use on 1-Year Outcomes in NSTEMI and STEMI Patients. JACC Adv 5 (2) 102574, 10.1016/j.jacadv.2025.102574.

Airagnes, G. (2025). État des lieux des addictions en France (in French only). Cahiers français (448) 30-40, 10.3917/cafr.448.0030.

Al Nasser, B. (2025). Vapotage, cannabis et cannabinoïdes de synthèse : une menace émergente pour la santé des jeunes. Une revue de littérature narrative [Vaping, cannabis, and synthetic cannabinoids: An emerging threat to youth health - A narrative literature review] (with English abstract). Alcoologie et Addictologie 45 (3) 105-113.

Alexandre, J.M., Moriceau, S., Ponsard, C., Beltran, V., Sarram, S., Dubernet, J. *et al.* (2025). Addiction severity index : un outil de cohérence d'équipe et de partenariat avec les personnes concernées (with English abstract). Le Courrier des Addictions 27 (3) 21-26.

Alhamidi, Z., Lacroix, C., Jouve, E., Soeiro, T., Eiden, C. and Micallef, J. (2026) Factors associated with cocaine use disorder: Results from the French nationwide repeated cross-sectional OPPIDUM study (2019-2023). Fundamental and Clinical Pharmacology 40 (3) e70081, 10.1111/fcp.70081.

Andler, R., Philippon, A., Pasquereau, A., Lahaie, E., Quatremère, G., Guignard, R. *et al.* (2025). Panorama épidémiologique des consommations de substances psychoactives en France [Epidemiological overview of psychoactive substance use in France] (with English abstract). La Revue du Praticien - Monographie 75 (5) 498-502.

André, C., Baudriller, A., Bellouard, M., Boudin, C., Carles, M., Gish, A. *et al.* (2025). Les cannabinoïdes semi-synthétiques : revue de la littérature et mise à jour [Semi-synthetic cannabinoids: Literature review and update] (with English abstract). Toxicologie Analytique et Clinique 37 (2) 204-222, 10.1016/j.toxac.2025.01.101.

Arbouche, N., Baudry, M., Blanchot, A., Walch, A., Berthelon, L., Farrugia, A. *et al.* (2026). Cannabis et mort inattendue du nourrisson : que révèlent les cheveux ? Bulletin de l'Académie Nationale de Médecine 210 (1) 53-56, 10.1016/j.banm.2025.07.011.

Autellet, A., Eiden, C., Batisse, A., Lacroix, C., Micallef, J., Fouilhe, N. *et al.* (2025) Novel psychoactive substances: Update of the French Addictovigilance Network Data. Emerging Trends in Drugs, Addictions, and Health 5 100192, 10.1016/j.etdah.2025.100192.

Barré, T., Cazorla, G., Di Beo, V., Lopez, F., Radoszycki, L., Maradan, G. *et al.* (2025) Patterns of Use and Patient-Reported Effects of Cannabinoids in People With PD: A Nationwide Survey. Parkinsons Dis 2025 2979089, 10.1155/padi/2979089.

Barré, T., Di Beo, V., Protopopescu, C., Lahaie, E., Andler, R., Nguyen Thanh, V. *et al.* (2025) Prevalence and factors associated with tobacco and cannabis co-use in France: Results from a national representative survey. Drug and Alcohol Dependence Reports 17 100381, 10.1016/j.dadr.2025.100381.

Batisse, A., Chaouachi, L., Thiery, J., Roussin, A., Chevalier, C., Caous, A.-S. *et al.* (2025). Pratique du chemsex en France : actualisation des données d'addictovigilance *(extraits)*. Focus sur les cathinones (in French only). Psychotropes Hors-série 125-130, 10.3917/psyt.hs.2025.0125.

Baumgarten, E., Corcos, M., Robin, M., Karila, L., Benyamina, A., Essadek, A. *et al.* (2025). Motivation de consommation de substances psychoactives chez les étudiants en médecine de trois facultés d'Île-de-France. Étude réalisée avant le Covid [Motivations for psychoactive substance use among medical students at three universities in Île-de-France: A pre-COVID study] (with English abstract). L'Information Psychiatrique 101 (8) 601-615, 10.1684/ipe.2025.2931.

Becker, L., Bucourt, E., Congard, A. and Arsandaux, J. (2026) Beyond the academic context: perceived stress, coping, and substance use among university students. Psychol Health Med in press, 10.1080/13548506.2026.2645958.

Begeman, A.H., Schellekens, A., van den Brink, W., Barta, C., Brynte, C., Crunelle, C.L. *et al.* (2025). Religiousness and self-control in patients with substance use disorder (SUD) and comorbid attention deficit/hyperactivity disorder (ADHD). Int J Soc Psychiatry 71 (7) 1271-1280, 10.1177/00207640251331973.

Blanchot, A., Kintz, P., Gonzalez, A., Veith, G., Graff, J., Raul, J.S. *et al.* (2026). New approach to document cannabis toxicity during pregnancy: a low abundance molecular species detection in long-term formalin-fixed paraffin embedded fetal tissues. A technological report. Int J Legal Med 140 1871-1880, 10.1007/s00414-026-03744-x.

Blay, M., Verne, M., Durpoix, A., Benmakhlouf, I. and Labaume, L. (2025). Clinical specificities of patients with substance use disorder and comorbid borderline personality disorder compared to patients with substance use disorder only: a retrospective study. Journal of Addictive Diseases 43 (3) 225-231, 10.1080/10550887.2024.2363038.

Bonny, P. (2025) Le chemsex, un type particulier d'addiction chez l'homme [Chemsex: A specific type of addiction in men] (with English abstract). L'Evolution Psychiatrique in press, 10.1016/j.evopsy.2025.09.004.

Bonny, P. (2025) L'addiction au chemsex : une perspective lacanienne sur la sexuation masculine [Chemsex addiction: A Lacanian perspective on male sexuation] (with English abstract). L'Evolution Psychiatrique in press, 10.1016/j.evopsy.2025.09.005.

Boudin, C., Eysseric-Guérin, H., Paysant, F., Stanke-Labesque, F., Scolan, V. and Willeman, T. (2025). Prevalence of psychoactive substance in fatal high-altitude accidents: A 10-year retrospective study in the French Alps. Toxicologie Analytique et Clinique 37 (4) 513-519, 10.1016/j.toxac.2025.05.004.

Braun, G., Blanc, J., Tosello, B., Baila, C.R., Barbier, M. and Castel, P. (2026) Consommation de cannabis chez la femme enceinte : une enquête épidémiologique [Cannabis use among

pregnant women: an epidemiological investigation] (with English abstract). Gynécologie Obstétrique Fertilité & Sénologie in press, 10.1016/j.gofs.2026.01.017.

Buathier, F., Lack, P., Chappuy, M., Bailly, F., Lespine, L.F. and Rolland, B. (2026). Prevalence and Factors Associated with Sexual Addiction in Men Who Have Sex with Men Seeking Treatment for Problematic Chemsex: Findings from the CHAMELEON Cross-Sectional Study. Arch Sex Behav 55 957-963, 10.1007/s10508-025-03392-z.

Cardozo, B., Hartley, S., Simon, N. and Alvarez, J.C. (2025). Understanding cannabis use and car crashes: Insights from a randomized trial using a driving simulator on THC blood levels and subjective measures of sleepiness and performance. Journal of Safety Research 95 109-116, 10.1016/j.jsr.2025.09.005.

Caré, W., Magny, R., Vodovar, D., Saint-Léger, F.B., Langrand, J., Laborde-Castérot, H. *et al.* (2025). Identification of 4F-MDMB-BICA using a molecular network strategy in a case of severe poisoning with coma. Journal of Analytical Toxicology 49 (5) 364-368, 10.1093/jat/bkaf019.

Ceoara, B., Dosquet, M., Sánchez-Rico, M., Geoffroy, P.A., Blanco, C., Limosin, F. *et al.* (2025). Association between sleep complaints and quality of life and the mediating role of substance use disorders: results from a nationally representative sample. J Psychiatr Res 189 479-487, 10.1016/j.jpsychires.2025.06.036.

Chabert, J., Icick, R., Cabé, J., Moisset, X., Godin, O., Gard, S. *et al.* (2025) Substance use disorders in outpatients with bipolar disorder and pain complaints. J Affect Disord 119693, 10.1016/j.jad.2025.119693.

Chevallier, C., Batisse, A., Monzon, E., Richard, N., Authier, N., Chenaf, C. *et al.* (2026) Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the Pharmacovigilance/Addictovigilance System From 2021 to 2024. Fundam Clin Pharmacol 40 (2) e70074, 10.1111/fcp.70074.

Chopra, R., Sylvestre, M.P., Pelekanakis, A., Doré, I., Omorou, A.Y. and O'Loughlin, J. (2025). Polysubstance use and mental health among young adults. Canadian Journal of Public Health 116 849-857, 10.17269/s41997-025-01035-3.

Chung, Y.R., Lam, D., Edel, Y., Caumes, E., March de Ribot, F., Fekkar, A. *et al.* (2025) Characteristics and outcomes of ocular candidiasis among patients who use buprenorphine intravenously. Med Mycol 63 (6) myaf048, 10.1093/mmy/myaf048.

Couraud, S., Molinier, O., Sabatini, M., Thomassin, S., Haouachi, R., Levrat, V. *et al.* (2025) Outcomes of cannabis smoking in patients with lung cancer: findings from KBP-CPHG-2020. Respiratory Medicine and Research 88 101174, 10.1016/j.resmer.2025.101174.

Daveluy, A., Perino, J., Titier, K., Peyriere, H., Autellet, A., Batisse, A. *et al.* (2025). Les NSP ou nouvelles substances psychoactives [NPS or new psychoactive substances] (with English abstract). Le Courrier des Addictions 27 (4) 23-30.

de Ternay, J., Plasse, A. and Rolland, B. (2026) The rising wave of cathinone use in people attending harm reduction facilities: a French repeated cross-sectional study (2019-2023). Addiction Science and Clinical Practice 21 31, 10.1186/s13722-026-00655-5.

Devault, D.A., Peyré, A., Cottereau, V., Pleignet, E. and Daveluy, A. (2025). How synthetic cannabinoid user profiles and consumption patterns can affect wastewater-based epidemiology. Environmental Science and Pollution Research 32 (58) 31108-31120, 10.1007/s11356-025-37106-8.

Devault, D.A., Peyré, A., Gish, A., Richeval, C., Pleignet, E., Cottereau, V. *et al.* (2025). Data for the epidemiological study of CH-PIATA in wastewater from the study of its presence over 12 months in "la Chimique" in Mayotte. Environmental Science and Pollution Research 32 (57) 30921-30929, 10.1007/s11356-025-36689-6.

Devault, D.A., Peyré, A., Gish, A., Richeval, C., Pleignet, E. and Gaulier, J.M. (2025). From the curb to the curve: population exposure to the synthetic cannabinoid receptor agonist MDMB-4en-PINACA in Mayotte. Environmental Science and Pollution Research 32 (57) 30958-30968, 10.1007/s11356-025-36744-2.

Donnadieu, H. (2025). Chemsex : une inquiétante évolution de la pratique [Chemsex: Worrying trends] (with English abstract). Psychotropes 31 (2-3) 113-117, 10.3917/psyt.312.0113.

Dos Santos, M., Briand Madrid, L., Olenine, A., Perreaut, L. and Roux, P. (2025). « J'ai aimé le flash de l'appareil photo, parce que nous, souvent, quand on se shoote, il fait noir » : mises en récits de la pratique d'injection dans la rue, avec la méthode photovoix ["I liked the camera flash, because when we shoot up, it's often dark": Stories of street injecting, using the photovoice method] (with English abstract). Psychotropes 31 (4) 115-133, 10.3917/psyt.314.0115.

Douchet, M.-A. and Neybourger, P. (2025). Le contrôle des usages juvéniles de cannabis. Les stratégies parentales pour obtenir des informations, limiter la consommation et maintenir le lien parent-enfant. Revue des politiques sociales et familiales (154) 131-140, 10.3917/rpsf.154.0131.

Douguet, F. (2025). Cannabis et grossesse : une diversité de pratiques de repérage parmi des sages-femmes libérales françaises [Cannabis and pregnancy: A diversity of screening practices among French independent midwives] (with English abstract). Psychotropes 31 (4) 93-113, 10.3917/psyt.314.0093.

Drevin, G., Briet, M., Ferec, S. and Abbara, C. (2025). "Goofballing": An emerging threat with clinical challenges. Therapeutic Drug Monitoring 47 (5) 691-695, 10.1097/ftd.0000000000001354.

Dugues, P., Rabai, A., Chenorhokian, S., Pfau, G., Cherki, S., Bellouard, M. *et al.* (2025). Emergence of counterfeit oxycodone tablets containing Nitazenes in France: First national alert and analytical characterization. Toxicologie Analytique et Clinique 37 (4) 529-539, 10.1016/j.toxac.2025.07.002.

Dugues, P., Robin, T., Bellouard, M., Chenorhokian, S., Triguel, M., Pfau, G. *et al.* (2026). Multi-analytical identification of the synthetic opioids cychlorphine and methiodone (IC-26) in drug seizures: first detection in Europe. Clinical Chemistry and Laboratory Medicine 64 (6) 1413-1424, 10.1515/cclm-2025-1428.

Duval, M., Istvan, M., Rousselet, M., Laforgue, E.J., Grall-Bronnec, M., Mauriat, C. *et al.* (2025). ESCAPE Study: Cannabidiol use in patients treated for substance use disorders, prevalence of use, and characteristics of users. European Addiction Research 31 (1) 35-46, 10.1159/000541887.

Eiden, C., Donnadieu, H. and Peyrière, H. (2025). Complications somatiques de l'usage de cocaïne (in French only). Santé Mentale n°301 50-55.

El Frenn, Y., Abbas, R., Hatahet, Z., El Asmar, K. and Ghossoub, E. (2025) Psychopathy dimensions and substance use: evidence from a non-institutionalized adult population. Frontiers in Psychiatry 16 1670589, 10.3389/fpsyt.2025.1670589.

El Ghachi, H., Oukhrib, M., Aziz, F., Benrazzouk, K., Gamrani, H., Soulimani, R. *et al.* (2025) Exploring the phytochemical and toxicological profile of Moroccan Cannabis sativa L. leaves extract: Behavioral, histological, and oxidative stress assessments. Journal of Ethnopharmacology 350 120058, 10.1016/j.jep.2025.120058.

El Haddad, R., Wiernik, E., Kab, S., Zins, M. and Airagnes, G. (2025) The association between cannabis use and adherence to COVID-19 public health guidelines: prospective analyses from the French CONSTANCES cohort and SAPRIS survey. Harm Reduction Journal 22 121, 10.1186/s12954-025-01278-w.

Fauvel, C., Dillinger, J.G., Bochaton, T., Levasseur, T., El Ouahidi, A., Zakine, C. *et al.* (2025). In-hospital and 1 year incremental prognostic value of drug abuse detection in acute heart failure. ESC Heart Fail 12 (4) 2736-2748, 10.1002/ehf2.15118.

Ferrer, F., Richard, D., Authier, N., Kerckhove, N., Pereira, B., Lopez, V. *et al.* (2026) Psychoactive substances in a general forensic autopsy population: prevalence and associations with cause and manner of death. Journal of Forensic and Legal Medicine 118 103079, 10.1016/j.jflm.2026.103079.

Fortin, D., Leroy, V., Carrieri, P., Matias, J. and Barré, T. (2025). Relationships between motives for cannabis and cannabidiol use in people who co-use: Results from the European Web Survey on Drugs. Drug and Alcohol Review 44 (6) 1666-1679, 10.1111/dar.14090.

Francès, P., Poddierohina, A. and Gaubert, R. (2026). Cannabis et pathologies bucco-dentaires, une problématique à envisager chez les jeunes adultes [Cannabis and oral health issues: a problem

to consider in young adults] (with English abstract). La Revue de Santé Scolaire et Universitaire 17 (98) 22-24.

Gish, A., Richeval, C., Gaulier, J.M. and Devault, D.A. (2025). Drug target residue selection for synthetic cannabinoids monitoring by wastewater-based epidemiology: case study of the AKB-48F (4F-ABINACA or 4F-ABUTINACA). Environmental Science and Pollution Research 32 (58) 31082-31089, 10.1007/s11356-025-37084-x.

Gonzalez, T., Melee, N., Beziat, M. and Lucet, C. (2025). Protoxyde d'azote : plaisir instantané, séquelles neurologiques durables (in French only). Le Courrier des Addictions 27 (3) 18-20.

Guerlais, M., Aquizerate, A., Daveluy, A., Lionnet, A., Gerardin, M., Duval, M. *et al.* (2025) Nitrous oxide in France: Evolution of complications reported to the French monitoring system in the context of information from health authorities and regulatory measures. International Journal of Drug Policy 144 Part 2 104172, 10.1016/j.drugpo.2023.104172.

Guillet, C., Endomba, F.T., Aravantinos, D., Hussami, A., Beye, F., Girod, J.C. *et al.* (2025). Sleep apnea syndrome in patients with methadone or buprenorphine. L'Encéphale 51 (4) 375-382, 10.1016/j.encep.2024.07.003.

Ibarra-Pertusa, L., Llorca-Bofí, V., Nicolau-Subires, E., Albert-Porcar, C., Adrados-Pérez, M., Arenas-Pijoan, L. *et al.* (2025) The hidden footprint of the pandemic: A three-year analysis of the impact of COVID-19 confinements on substance addiction. Psiquiatría Biológica 32 (3) 100732, 10.1016/j.psiq.2025.100732.

Jaëck, M., El Bèze, N., Dillinger, J.G., Trimaille, A., Chaussade, A.S., Thuaire, C. *et al.* (2025). Psychoactive drug use and prognosis in patients with cancer presenting with acute cardiovascular disease. Arch Cardiovasc Dis 118 (8-9) 446-456, 10.1016/j.acvd.2025.03.122.

Janssen, E. and Vuolo, M. (2025) Extending the scope of the capture-recapture experiment: a multilevel approach with random effects to provide reliable estimates at national level. Epidemiologic Methods 14 (1) 20250011, 10.1515/em-2025-0011.

Janssen, E., Vuolo, M., Véron, S. and Spilka, S. (2026). Patterns and determinants of polystimulant use among patients seeking treatment for stimulant use disorders. Substance Use and Misuse 61 (7) 1064-1071, 10.1080/10826084.2025.2593572.

Jauffret-Roustide, M. (2025). Cocaïne, une lecture sociologique (in French only). Santé Mentale n°301 78-81.

Jean, F.A.M., Montagni, I., Schwartz, A.N., Navarro, M.C., Galesne, C., Macalli, M. *et al.* (2026). Illicit substance use and attention deficit hyperactivity disorder symptoms among French university students: a multiple correspondence analysis and a cluster analysis. Eur Arch Psychiatry Clin Neurosci 276 (1) 327-337, 10.1007/s00406-025-02092-y.

Julien, C., Bernard, L. and Brejard, V. (2025) Dissociative Experiences and Substance Use Disorder in Adulthood After Childhood Trauma: A Systematic Review of the Literature. Clin Psychol Eur 7 (4) e15877, 10.32872/cpe.15877.

Kadri, A., Clergue-Duval, V., Lambert, C., Atger, L., Chouchana, M., de Chazeron, I. *et al.* (2025). Is cocaine use associated with intimate partner violence in patients from addiction centers? Substance Use and Misuse 60 (11) 1577-1582, 10.1080/10826084.2025.2506144.

Kang, J., Kim, H.J., Lark, A.R.S., Mir, F.A., Park, J., Son, Y. *et al.* (2025). Association of Everyday Discrimination With Drug Use During the COVID-19 Pandemic in the All of Us Research Program. Psychiatry Investig 23 (1) 118-129, 10.30773/pi.2025.0234.

Kennedy, G., Czerwinska, J., Battal, D., Kintz, P. and Abbate, V. (2025) The analysis and detection of synthetic cathinones in hair - state of the art, challenges, and future aspects. Emerging Trends in Drugs, Addictions, and Health 5 100267, 10.1016/j.etdah.2025.100267.

Kfoury, R., Salameh, P. and Peyriere, H. (2025) From knowledge to attitude: design and initial validation of scales for assessing psychoactive substance consumption among university students. Frontiers in Public Health 13 1713133, 10.3389/fpubh.2025.1713133.

Lalanne, L., Kirchherr, S., Audran, M., de Dinechin, S., Hamelin, N., Chauvin, C. *et al.* (2025) Episodic memory and inhibitory control in people who inject substances results of cohort COSINUS study. BMC Psychiatry 25 853, 10.1186/s12888-025-07223-2.

Lalanne, L., Lutz, P.-E., Caparros-Roissard, A., Ruppert, E., Waeckerle, G., Scherer, C. *et al.* (2025) Integrative exploration of bio-psycho-social determinants of DSM-5 severity levels of opioid use disorder: the BEBOP cohort study protocol. BMJ Open 15 (10) e093358, 10.1136/bmjopen-2024-093358.

Lalanne, L., Lutz, P.-E., Caparros-Roissard, A., Waeckerle, G., Scherer, C., Lebreton, M. *et al.* (2025). Exploration des déterminants bio-psycho-sociaux des niveaux de sévérité du trouble de l'usage d'opioïdes : la cohorte BEBOP [Exploring the biopsychosocial determinants of opioid use disorder severity: The BEBOP cohort] (with English abstract). Psychotropes 31 (2-3) 97-111, 10.3917/psyt.312.0097.

Lapeyre-Mestre, M., Micallef, J., Hacquet, R. and Jouanjus, E. (2025). Pharmacovigilance in the field of addiction: challenges and emerging solutions. Expert Review of Clinical Pharmacology 18 (12) 989-1003, 10.1080/17512433.2025.2600414.

Laroche, M.L., Labetoulle, M., Jouanjus, E., Kröger, E. and Zongo, A. (2025) Cannabinoids and adverse convulsive effects: A pharmacovigilance and addictovigilance analysis of cases reported in France. Fundamental and Clinical Pharmacology 39 (4) e70028, 10.1111/fcp.70028.

Laureillard, D., Binh, N.T., Vinh, V.H., Hong, T.T., Quillet, C., Thanh, N.T.T. *et al.* (2025) High efficiency and safety of hepatitis C treatment among people who inject drugs in Vietnam. Journal of Viral Hepatitis 32 (11) e70090, 10.1111/jvh.70090.

Le Carpentier, E., Helesbeux, M., Biering, V., Aquizerate, A., Rousselet, M., Barrangou-Poueys-Darlas, M. *et al.* (2025). Enhancing addiction care: Benefits of urinary screening with LC-HRMS (liquid chromatography-high resolution mass spectrometry) for psychoactive substances and drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry 141 111465, 10.1016/j.pnpbp.2025.111465.

Lefint, R., Gladieux, N., Faillie, J., Gish, A., Hakim, F., Grenier, C. *et al.* (2025). Mise à jour 2023-2024 des cas d'intoxication identifiés dans un contexte de pratique de chemsex au laboratoire de toxicologie du CHU de Lille : les tendances actuelles [Update 2023-2024 of cases of intoxication identified as linked to the practice of chemsex, at the toxicology laboratory of Lille University Hospital: Current trends] (with English abstract). Toxicologie Analytique et Clinique 37 (3) 376-385, 10.1016/j.toxac.2025.03.002.

Lestienne, M., Macgregor, A., Surig, L., Donnadieu, H., Mondesert, E., Eiden, C. *et al.* (2026). Psychiatric and neurocognitive adverse events in young users of nonmedical nitrous oxide. Journal of Clinical Psychopharmacology 46 (1) 23-29, 10.1097/JCP.0000000000002070.

Maillot, A., Guyon, J., Ma-Tsi-Leong, M., Berly, L., Weisse, F., Mahé, A. *et al.* (2025) Clinical and toxicological epidemiology of intoxications by new psychoactive substances in Reunion Island. International Journal of Emergency Medicine 18 260, 10.1186/s12245-025-01055-3.

Martin, N., Beyls, C., Zeitouni, M., Bohbot, Y., Stracchi, V., Sroutta-Paillusseau, S. *et al.* (2025) Cannabis use among young adults with acute coronary syndrome: impact on initial presentation and long-term prognosis. Heart in press, 10.1136/heartjnl-2025-326777.

Matar, S., Dupin, N., Petit, A.C., Gaillard, R., Aractingi, S. and Oulès, B. (2025). Cutaneous manifestations associated with substance use disorders. JAAD Reviews 4 206-219, 10.1016/j.jdrv.2025.03.016.

Mauries, S., Julia, Z., Duroy, D., Borand, R., Phung, B.C., Rouvrais, M. *et al.* (2026). Clinical and socio-demographic characteristics associated with the severity of chemsex practice. Substance Use and Misuse 61 (7) 1072-1079, 10.1080/10826084.2025.2596682.

Medigue, I., Catoire, S., Peyron, C., Geoffroy, P.A., Bernabeu, T., Peter-Derex, L. *et al.* (2025) Longitudinal disturbances of objective sleep architecture in cocaine use disorder: A translational systematic review. Neurosci Biobehav Rev 176 106278, 10.1016/j.neubiorev.2025.106278.

Menecier, P. and Dorey, J.-M. (2025). Les addictions du sujet âgé... À travers ce qu'elles ne sont pas [Addiction in older adults… Making progress by defining what they are not] (with English abstract). Psychotropes 31 (2-3) 23-40, 10.3917/psyt.312.0023.

Michel, L., Trouiller, P., Gruyelle, F., Moulis, L., Vaquier de Labaume, G., Charmet, T. *et al.* (2026). Prévalence des troubles psychiatriques chez les hommes et femmes faisant usage de crack à Paris (Étude ANRS-Icone 2) : nécessité d'une adaptation de l'offre de soins. Bulletin Épidémiologique Hebdomadaire (1) 2-9.

Mirailles, R., Delmas, C., Toupin, S., Bouleti, C., Trimaille, A., Schurtz, G. *et al.* (2026) Association between recreational drug use and cardiovascular events post-hospitalization in France. Circ Popul Health Outcomes 19 (2) e011905, 10.1161/circoutcomes.124.011905.

Moulis, L., Michel, L., Trouiller, P., Charmet, T., Gruyelle, F., Joly, J. *et al.* (2025). Diagnostic performances of a rapid screening tool for detection of psychiatric symptomatology in an urban community setting of people who use drugs in France. Journal of Dual Diagnosis 21 (4) 280-295, 10.1080/15504263.2025.2557194.

Nadarajan, D., Laimou-Geraniou, M., Chappell, A., Baduel, C., Bijlsma, L., Boogaerts, T. *et al.* (2026) Wastewater analysis as a global toxicovigilance tool for the monitoring of new psychoactive substances. Water Research 289 124847, 10.1016/j.watres.2025.124847.

Najdini, M., Frigaux, A., Mathieu, J., Shadili, G., Guenoun, T., Vlachopoulou, X. *et al.* (2025) ATICC: a mixed-methods study on addiction, trauma, and immigration among vulnerable young adults in the Grand Est youth network. BMC Psychol 13 (1) 582, 10.1186/s40359-025-02738-5.

Najdini, M., Mathieu, J., Shadili, G., Frigaux, A., Ménauges, M., Mouton, C. *et al.* (2025). Substance use prevalence among immigrants by generational status in Europe: A systematic review and meta-analysis. Alcohol, Clinical and Experimental Research 49 (7) 1381-1391, 10.1111/acer.70091.

Negrault, N., Puech, B., Guyon, J., Daveluy, A., Bastard, S., Mete, D. *et al.* (2025). Case series of severe intoxications associated with new psychoactive substances on Reunion Island: Clinical description and diagnostic challenges. Toxicologie Analytique et Clinique 37 (3) 391-398, 10.1016/j.toxac.2025.01.096.

Newell, L.R., Fouillen, K.J., Orliaguet, M., Kichenin, J. and Boisramé, S. (2025) Oral health effects of ecstasy (MDMA) and methamphetamine: a narrative review. Frontiers in Oral Health 6 1645445, 10.3389/froh.2025.1645445.

Nguyen, A. (2025). Les cannabinoïdes de synthèse, une consommation en hausse [Synthetic cannabinoids: Consumption on the rise] (with English abstract). Actualités Pharmaceutiques 64 (646) 29-32, 10.1016/j.actpha.2025.03.008.

Obradovic, I. and Veron, S. (2025). Cocaïne : des signaux sanitaires au rouge (in French only). Santé Mentale n°301 38-43.

Paccoud, O., Lortholary, O., Imbert, S., Letscher-Bru, V., Boukris-Sitbon, K., Obadia, T. *et al.* (2025) Yeast fungaemia among injection drug users in France (2012–2022): a cross-sectional observational study. The Lancet Regional Health - Europe 55 101365, 10.1016/j.lanepe.2025.101365.

Pavirani, L., Jakubiec, L., Daveluy, A., Cazanave, C., Desnavailles, P. and Fatseas, M. (2026) Addictive disorders and correlates in the context of chemsex practices: A French online survey. Addictive Behaviors Reports 23 100679, 10.1016/j.abrep.2026.100679.

Pavirani, L., Seelarbokus, B.A., Marinelli, L., Desnavailles, P., Berthoz, S. and Fatseas, M. (2026) Associations Between Vitamin D Status and Clinical Presentation Among French Inpatients With Substance Use Disorders. Addict Biol 31 (1) e70110, 10.1111/adb.70110.

Pélissier-Alicot, A.L., Fabresse, N., Petitcollin, A., Costagliola, R., Dubertrand, C., Baillif-Couniou, V. *et al.* (2026) Unusual Case of Fatal Virtual Chemsex Session Involving 3-Chloromethcathinone (3-CMC). Toxics 14 (2) 131, 10.3390/toxics14020131.

Perrard, L., Clément, A., Pezel, T., Henry, P. and Dillinger, J.G. (2025). Consommation de drogues récréatives et syndrome coronarien aigu (in French only). Archives des Maladies du Coeur et des Vaisseaux - Pratique 2025 (341) 16-22, 10.1016/j.amcp.2025.07.011.

Perrin, S., Delaquaize, H., Coppel, A. and Bastiani, P. (2026). Être une femme qui a consommé et travaille sur les drogues. Enjeux liés au genre dans les trajectoires d'usage et de prise en charge [Being a woman who has used drugs and works in the field of drug use: Gender issues in drug use trajectories and care pathways] (with English abstract). Psychotropes 32 (1-2) 175-210, 10.3917/psyt.321.0175.

Peter-Derex, L., Fort, E., Putois, B., Martel, N., Ricordeau, F., Bastuji, H. *et al.* (2025). Determinants of substance use patterns in patients with narcolepsy type 1: A multi-center comparative cross-sectional study. Sleep Medicine 129 148-166, 10.1016/j.sleep.2025.02.037.

Peyrière, H., Batisse, A., Sam-Laï, N.F., Daveluy, A., Fournier-Choma, C., Deheul, S. *et al.* (2025). Contribution of Addictovigilance data to assess adverse-events linked to psychoactive substances in children and adolescents. British Journal of Clinical Pharmacology 91 (10) 2957-2968, 10.1002/bcp.70133.

Phan, O. and Har, A. (2025). Troubles liés à l'usage du cannabis à l'adolescence [Cannabis use disorders in adolescence] (with English abstract). Journal de Pédiatrie et de Puériculture 38 (6) 317-324, 10.1016/j.jpp.2025.06.001.

Pradère, P., Marinello, A., Vasseur, D., Naltet, C., Moaca, S., Le Pavec, J. *et al.* (2026). The impact of dual cannabis and tobacco smoking in young patients with lung cancer: results from the prospective "Environment and Lung Cancer" study. CHEST 169 (3) 819-829, 10.1016/j.chest.2025.09.017.

Raingeard, T., Soeiro, T., Victorri-Vigneau, C., Le Boisselier, R., Boucher, A., Fouilhé Sam-Laï, N. *et al.* (2026) Health risks associated with non-medical use of ketamine in France: National surveillance insights from the French Addictovigilance Network, 2019-2023. Journal of Psychopharmacology in press, 10.1177/02698811261420018.

Robert, F. (2025). « Trip » sous LSD : le psychédélisme des sixties [Trip on LSD: The Psychedelic Sixties] (with English abstract). Drogues, santé et société 23 (1) 17-38.

Rolland, F., Frajerman, A., Falissard, B., Benyamina, A., Diquet, B., Vinchon, F. *et al.* (2025). COVID-19 pandemic's impact on French Health Students' consumption of substances - A mixed analysis of their substance use. L'Encéphale 51 (5) 486-491, 10.1016/j.encep.2024.10.003.

Rollier, S., Lehoux, T., Angerville, B., Vaissade, L., Lacoste, J. and Merle, S. (2025). Prevalence of problematic drug use in Martinique in 2006: The NEMO study. L'Encéphale 51 (4) 413-417, 10.1016/j.encep.2024.09.002.

Romeo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V. *et al.* (2025). Significant psychedelic experiences evaluated for mystical characteristics associated with cannabis use reduction and psychological flexibility improvement: A naturalistic cross-sectional retrospective survey. Journal of Psychoactive Drugs 57 (4) 374-385, 10.1080/02791072.2024.2375720.

Rustin, M., Lecronier, M., Mayaux, J. and Decavèle, M. (2025). Fatal levamisole-associated multifocal inflammatory leukoencephalopathy following levamisole-adulterated cocaine use. Clinical Toxicology 63 (9) 687-689, 10.1080/15563650.2025.2528997.

Sperle, I., Seyler, T., Pericoli, F., Duffell, E., Hutchinson, S., Jauffret-Roustide, M. *et al.* (2025) Standardising monitoring data on drug-related infectious diseases among people who inject drugs in Europe - an update of the European Union Drugs Agency technical protocol, 2024. Eurosurveillance 30 (30), 10.2807/1560-7917.Es.2025.30.30.2500007.

Storck, W., Elbaz, M., Vindis, C., Déguilhem, A., Lapeyre-Mestre, M. and Jouanjus, E. (2025). Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis. Heart 111 (22) 1047-1056, 10.1136/heartjnl-2024-325429.

Sznitman, S.R., Potter, G.R., Grigg, J., Granville, A., Hakkarainen, P., Decorte, T. *et al.* (2025) Are cannabis use problems comparable across individuals using for recreational and medical purposes? An international cross-sectional study of individuals who use self-grown cannabis. International Journal of Drug Policy 144 Part 3 104263, 10.1016/j.drugpo.2023.104263.

Tran, H.T., Duong, H.T., Pham, K.M., Nguyen, B.T., Vallo, R., D'Ottavi, M. *et al.* (2025). Hepatitis C virus incidence trend and its risk factors among people who inject drugs in Hai Phong, Vietnam. Hepatol Int 19 1077-1086, 10.1007/s12072-025-10856-w.

Vallée, A. (2025). Lifetime Cannabis Use and Augmentation Index in Middle-Aged Adults. Am J Hypertens 38 (11) 914-923, 10.1093/ajh/hpaf105.

von Fabeck, K., Glaizal, M. and Simon, N. (2025). Body packers and body stuffers: cocaine intoxications reported to French poison centers (January 1, 2020-December 31, 2024). Clinical Toxicology 63 (11) 952-958, 10.1080/15563650.2025.2546562.

von Fabeck, K., Glaizal, M., Schmitt, C., Torrents, R. and Simon, N. (2026) Invisible victims: rising pediatric cocaine exposures in France (2020-2024) - insights from the national poison center database. Front Toxicol 8 1732108, 10.3389/ftox.2026.1732108.

Wallez, S., Eren, F., Lahaie, E., Spilka, S., Rezag Bara, S.F., Bayle, G. *et al.* (2026) Factors associated with different cannabis supply methods: results from the French 2017 ESCAPAD and Health Barometer surveys. Journal of Cannabis Research 8 19, 10.1186/s42238-025-00372-x.

Yaya, I., Kassang, P., Soedje, K.M.A., Hategou, K., Sanwogou, G.L., Patassi, A.A. *et al.* (2026) Prevalence, patterns, and associated factors of psychoactive substance use among people living with HIV in Lomé, Togo : a cross-sectional study. BMC Public Health 26 1128, 10.1186/s12889-026-26751-4.

Zhang, L., Zhu, N., Sjölander, A., Nourredine, M., Li, L., Garcia-Argibay, M. *et al.* (2025) ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ 390 e083658, 10.1136/bmj-2024-083658.

Ziehfreund, S., Saak, M., Schaal, A., Mazilu, R., Mahé, E., Hajj, C. *et al.* (2025) Addiction and chronic skin diseases: A Pan-European study on prevalence, associations and patient impact. J Eur Acad Dermatol Venereol in press, 10.1111/jdv.70245.

(3) Demand reduction (including prevention, treatment, harm reduction, reintegration and clinical treatment research) = 82 articles

Agostinucci, M. and Orival, T. (2025). Trajectoire sportive à l'épreuve de l'addiction : étude d'un parcours de vie [A sporting career tested by addiction: a life-course study] (with English abstract). Soins Psychiatrie 46 (360) 37-41, 10.1016/j.spsy.2025.07.009.

Arwidson, P. (2025). Ce qui fonctionne en matière de prévention des addictions [What works in addiction prevention] (with English abstract). La Revue du Praticien - Monographie 75 (5) 503-506.

Aubin, H.-J. (2025). Structures spécialisées dans la prise en charge des addictions [Addiction care system in France] (with English abstract). La Revue du Praticien - Monographie 75 (5) 519-522.

Barroyer, M., Kaldé-Frientz, A., Garnier, C., Kivits, J., Paille, F. and Omorou, A. (2025). Les trajectoires addictives et de services en Lorraine : l'étude TAS [Addiction and care pathways in Lorraine: The TAS study] (with English abstract). Santé Publique 37 (4) 85-96, 10.3917/spub.254.0085.

Bastien, M., Mezaache, S., Donadille, C., Madrid, L.B., Lebrun, M., Martin, V. *et al.* (2025) Willingness to use a drug checking service for cannabis and cannabis-based products: results from an online survey of people who regularly use cannabis in France. Harm Reduction Journal 22 126, 10.1186/s12954-025-01274-0.

Begnaud, A., Cabelguen, C., Challet-Bouju, G., Leboucher, J., Schreck, B. and Grall-Bronnec, M. (2026) Clinical outcomes of addictive disorders six months after ADHD Diagnosis: Insights from the START study. Addictive Behaviors 173 108557, 10.1016/j.addbeh.2025.108557.

Benyamina, A. (2025). Comprendre les addictions (in French only). Cahiers français (448) 14-21.

Bertrand, B. (2025). Panorama international des Salles de Consommation à Moindre Risque [International overview of Drug Consumption Rooms] (with English abstract). Psychotropes 31 (2-3) 169-179, 10.3917/psyt.312.0169.

Bertrand, B. (2025). Attitudes des professionnels de première ligne de la région PACA face à la Réduction des Risques et des Dommages : connaissances, perceptions et besoins [Attitudes of frontline professionals in the PACA region toward harm reduction: knowledge, perceptions, and needs] (with English abstract). Alcoologie et Addictologie 45 (3) 7-21.

Bezo, A., Roméo, B., Le Strat, Y., Strika-Bruneau, L., Benyamina, A. and Hermand, M. (2026). Does the perception of risk associated with psychedelics use differ in physicians according to their belief of effectiveness? Journal of Psychoactive Drugs 58 (1) 1-6, 10.1080/02791072.2024.2424263.

Bichard, I., Odoul, M. and Derche, N. (2025). Le parcours de soins chemsex au Checkpoint Paris, centre de santé sexuelle d'approche communautaire [Health care provision at Checkpoint Paris, a community-based sexual health center] (with English abstract). Psychotropes 31 (2-3) 119-125, 10.3917/psyt.312.0119.

Bless, P., Blaser, D., Castelain, T., Pugnale, S., Ribordy, V. and Guechi, Y. (2025) Clinical Approach to Acute Recreational Drug Intoxication in the Emergency Setting: A Practical Guide Based on Swiss Experience. Toxics 13 (12) 1034, 10.3390/toxics13121034.

Bou Nassif, Y., Benyamina, A., Rahioui, H. and Varescon, I. (2025). Une thérapie intégrative française du trouble lié à l'usage de cannabis à l'adolescence : description de la thérapie TIMCA, protocole de l'étude et caractéristiques psychosociales des participants (in French only). Alcoologie et Addictologie 45 (3) 56-64.

Boulze-Launay, I., Rigaud, A. and Gal, C. (2025). Traumatisme de la naissance et addictions: approche théorique et perspectives thérapeutiques du climat d'angoisse…. Canadian Journal of Psychoanalysis = Revue canadienne de psychanalyse 33 (1) 109-127.

Boumaiza, M. (2025) La complexité des demandes esthétiques chez les personnes consommant des substances psychoactives : entre quête identitaire, stigmates corporels et dilemmes éthiques [The complexity of aesthetic demands among psychoactive substance users: Between identity quest, bodily stigma, and ethical dilemmas] (with English abstract). Éthique & Santé in press, 10.1016/j.etiqe.2025.11.003.

Brynte, C., Schellekens, A., Konstenius, M., Begeman, A.H.A., Crunelle, C.L., Demetrovics, Z. *et al.* (2026) Predictors of treatment success in patients with substance use disorder (SUD) and co-morbid attention deficit/hyperactivity disorder (ADHD): Results from the International Naturalistic Cohort Study of ADHD and SUD (INCAS). Eur Neuropsychopharmacol 106 112783, 10.1016/j.euroneuro.2026.112783.

Cabé, J. (2026). Buprénorphines d'action prolongée : anticiper et gérer les réactions au site d'injection en pratique clinique [Long-acting buprenorphine: anticipating and managing injection site reactions in clinical practice] (with English abstract). Le Courrier des Addictions 28 (1) 30-32.

Cabelguen, C., Challet-Bouju, G., Thiabaud, E., Donnio, Y., Lefebvre, L., Hardouin, J.B. *et al.* (2026) Randomised controlled trial on the efficacy of adding cognitive remediation therapy to methylphenidate in adult patients with attention deficit hyperactivity disorder and addictive disorders (META): CRT in ADHD and addiction - META study protocol. BMJ Open 16 (3) e111698, 10.1136/bmjopen-2025-111698.

Chappard, P. and Pourchon, F. (2026). Pour une réduction des risques émancipatrice [Toward emancipatory harm reduction] (with English abstract). Psychotropes 32 (1-2) 223-238, 10.3917/psyt.321.0223.

Chapuy, M. and Frauger, E. (2025). Naloxone : l'antidote qui sauve des vies. Histoire, impact et déploiement des programmes à travers le monde [Naloxone, the life-saving antidote: History, impact, and international programs] (with English abstract). Psychotropes 31 (2-3) 127-143, 10.3917/psyt.312.0127.

Charvet, C. (2026). Marmottan et le temps : penser l'addiction comme pathologie temporelle [Marmottan and time: Thinking of addiction as a temporal pathology] (with English abstract). Psychotropes 32 (1-2) 103-117, 10.3917/psyt.321.0103.

Couteron, J.-P. and Longbottom, S. (2026). Les nouvelles communautés thérapeutiques [New therapeutic communities] (with English abstract). Psychotropes 32 (1-2) 159-173, 10.3917/psyt.321.0159.

Dano, C. and Hache, P. (2025) Usage des substances psychoactives : prévention en milieu professionnel - Recommandation (in French only). Archives des Maladies Professionnelles et de l'Environnement 86 (5) 102943, 10.1016/j.admp.2025.102943.

Dematteis, M. (2025). Alcool et cocaïne : Prise en charge et nouveaux traitements (in French only). Alcoologie et Addictologie (N° spécial) 75-77.

Dervaux, A. (2025). Intelligence artificielle en addictologie : intérêts et limites [Artificial intelligence in addictology: Potential uses and limitations]. L'Information Psychiatrique 101 (9) 707-713, 10.1684/ipe.2025.2951.

Dugarin, J. (2026). Quelques réflexions sur les origines de l'addictologie en France et ses rapports avec la psychiatrie [Some reflections on the origins of addiction studies in France and its relationship with psychiatry] (with English abstract). Psychotropes 32 (1-2) 119-140, 10.3917/psyt.321.0119.

Dumont, G. and Jauffret-Roustide, M. (2025) Violence in harm reduction: Exploring the social, political, and emotional conditions of harm reduction work. Medical Anthropology Quarterly e70055, 10.1111/maq.70055.

Enjolras, N. (2025). De nouveaux métiers en addictologie : exemple des patients experts [New professions in addictology: The case of peer support specialists] (with English abstract). Psychotropes 31 (2-3) 41-60, 10.3917/psyt.312.0041.

Enjolras, N. (2025). Pair-aidance : « Avec vous, je peux parler sans filtre » (in French only). Santé Mentale n°301 68-73.

Faye, R.A.Y., Desclaux, A. and Diagne, A. (2025) The gender factor in meeting the needs of women who use drugs in Senegal. Harm Reduction Journal 22 (1) 50, 10.1186/s12954-025-01186-z.

Frauger, E. and Chappuy, M. (2025). Naloxone en France : prévention des surdoses d'opioïdes grâce à des programmes innovants [Naloxone in France: Preventing opioid overdoses through innovative programs] (with English abstract). Psychotropes 31 (2-3) 145-167, 10.3917/psyt.312.0145.

Frenette, R. (2026). Ce que la nostalgie peut faire pour l'addiction (in French only). Revue Médecine et Philosophie (14) 9-17.

Gaillard, M. and Gache, P. (2025). L'entretien motivationnel, un levier relationnel pour faciliter le changement [Motivational interviewing: A relationship lever to facilitate change] (with English abstract). Psychotropes 31 (2-3) 199-215, 10.3917/psyt.312.0199.

Garbolino, S., Dos Santos, M., Pimond, O., Sayag, L., Khatmi, N. and Roux, P. (2025) "You have to love the party setting": an ethnography of the blurred lines between roles and experiential knowledge in a French harm reduction collective working in the party setting. Harm Reduction Journal 22 73, 10.1186/s12954-025-01209-9.

Gerbaud, C., Debette-Gratien, M., Guillouche, P., François, C., Dillenschneider, A., Reiller, B. *et al.* (2026) Managing Hepatitis C in Addiction Care Centers: Results of the French Real-Life NéoVie Study. J Viral Hepat 33 (2) e70121, 10.1111/jvh.70121.

Gilles, S. (2025) Vernacular and discursive harm reduction: an ethnography of an online drug community. Harm Reduction Journal 22 53, 10.1186/s12954-025-01180-5.

Grzych, G., Diesnis, R., Dupré, T., Niguet, J.P., Gernez, E., Denimal, D. *et al.* (2025) Addressing the Global Challenge of Nitrous Oxide Misuse Through a Multidisciplinary Approach: Example of the PROTOSIDE Network. Toxics 13 (6) 466, 10.3390/toxics13060466.

Grzych, G., Lee, G.R., Alpdemir, M., Gernez, E., Anseeuw, K., Bjorke-Monsen, A.L. *et al.* (2026). Addressing the silent epidemic of recreational nitrous oxide use: a position, call to action and recommendations by the European Federation of Clinical Chemistry and Laboratory Medicine Committee on Biological Markers of Nitrous Oxide Abuse. Clinical Chemistry and Laboratory Medicine 64 (4) 813-820, 10.1515/cclm-2025-1060.

Harris, M.G., Kazdin, A.E., Hwang, I., Manoukian, S.M., Sampson, N.A., Stein, D.J. *et al.* (2025) Pathway to effective treatment for common mental and substance use disorders in the World Mental

Health Surveys: Perceived need for treatment. Int J Ment Health Syst 19 (1) 17, 10.1186/s13033-025-00666-w.

Henneguelle, A. and Weatherburn, D. (2025) Does diverting minor drug offenders reduce recidivism? Cannabis cautioning in Australia. International Journal of Drug Policy 145 105008, 10.1016/j.drugpo.2025.105008.

Howardson, B.O., Vérillaud, B., Herman, P. and Marc, M. (2025). Management of cocaine-induced midline lesion (CIMDL) extended to skull base: a case report and systematic review. Eur Arch Otorhinolaryngol 283 59-67, 10.1007/s00405-025-09612-5.

Jauffret-Roustide, M. (2025) Reprint of: Monitoring HIV, HCV and HBV among people who use drugs in France. A reflective feed-back on a 25-year experiment based on mixed methods. The ANRS-Coquelicot survey. International Journal of Drug Policy 144 Part 1 104727, 10.1016/j.drugpo.2025.104727.

Jauffret-Roustide, M., Bertrand, K. and Groupe Polytoux (2025). Une expérience narco-féministe de recherche participative : La place des savoirs expérientiels liés à l'usage de drogues dans l'évaluation des politiques de soins liés aux addictions, au prisme du genre [A narco-feminist experiment in participatory research : The place of experiential knowledge relating to drug use in the evaluation of addiction treatment and harm reduction care policies, from a gender perspective] (with English abstract). Revue française des affaires sociales (251) 93-112, 10.3917/rfas.251.0093.

Jauffret-Roustide, M. and Wdowiak, L. (2025). « Plafond de verre » sur la politique de réduction des risques. Les salles de consommation en France (in French only). La Revue Nouvelle (253) 40-50, 10.3917/rn.253.0040.

Joyce, K.M., Delaquis, C.P., Alsaidi, T., Sulymka, J., Conway, A., Garcia, J. *et al.* (2025) Treatment for substance use disorder in mothers of young children: A systematic review of maternal substance use and child mental health outcomes. Addictive Behaviors 163 108241, 10.1016/j.addbeh.2024.108241.

Karila, L. and Donnadieu, H. (2025). Addiction à la cocaïne : approches pharmacologiques (in French only). Santé Mentale n°301 56-60.

Karsinti, E. (2025). Trouble d'usage de cocaïne et psychothérapies (in French only). Santé Mentale n°301 44-49.

Krebs, Z. (2026). Les poupées russes de la parentalité en situation d'addiction : tisser une toile de liens (with English abstract). Enfances et Psy (106) 119-126.

Labrèze, L. (2025). Le cannabis thérapeutique en oncologie : bilan d'étape de l'expérimentation nationale pilotée par l'Agence nationale de sécurité du médicament (in French only). Phytothérapie 23 (2) 57-69.

Larabi, I.A., Tournoud, C., Fabresse, N., Gallart, J.-C., Kintz, P., Alvarez, J.-C. *et al.* (2026). Soumission chimique : entre urgence sociétale et rigueur scientifique - Le rôle des sociétés savantes [Drug facilitated crimes: At the crossroads of societal urgency and scientific standards - The role of scientific societies] (with English abstract). Toxicologie Analytique et Clinique 38 (1) 93-100, 10.1016/j.toxac.2025.08.008.

Lignier, B. (2025). Addictions et douleurs : entre répétition traumatique et quête d'états non ordinaires de conscience [Addictions and pain: Between traumatic repetition and the quest for altered states of consciousness] (with English abstract). Perspectives Psy 64 (4) 408-416.

Maillot, A. and Mété, D. (2025). Campagne de sensibilisation aux cannabinoïdes de synthèse à La Réunion : évaluation et perspectives (in French only). Alcoologie et Addictologie (N° spécial) 13-20.

Mété, D., Sandaye, F., Rojoa, B. and Gado, E. (2025). Programme KAPAB (with English abstract). Alcoologie et Addictologie (N° spécial) 41-45.

Morel, A. (2026). L'addictologie dans l'impasse des neurosciences : comment en sortir ? [Addiction studies at an impasse in neuroscience: How to move forward?] (with English abstract). Psychotropes 32 (1-2) 69-101, 10.3917/psyt.321.0069.

Murys-Chaix, E., Iakimova, G. and Szekely, D. (2025). Intérêt de la psychothérapie d'acceptation et d'engagement et de la thérapie fondée sur la compassion pour soutenir le maintien de l'abstinence dans les polyaddictions. Annales Médico-psychologiques, revue psychiatrique 183 (9) 903-915, 10.1016/j.amp.2023.10.005.

Naudon, A.-S. (2025). Les cathinones de synthèse, une prévention indispensable dans les milieux à risque [Synthetic cathinones, an essential preventive measure in high-risk environments] (with English abstract). Actualités Pharmaceutiques 64 (646) 33-36, 10.1016/j.actpha.2025.03.009.

Padovani, R., Cohen, J., Padovani, A., Laurent, C., Huc, P., Wendling, J. *et al.* (2025). Efficacité de la stimulation magnétique transcrânienne répétitive (RTMS) pour la prise en charge de la douleur neuropathique chronique chez les utilisateurs d'opioïdes : Une approche exploratoire [Effectiveness of repetitive transcranial magnetic stimulation (rTMS) for the treatment of chronic neuropathic pain in opioid users] (with English abstract). Alcoologie et Addictologie (N° spécial) 23-34.

Papias, E., Roux, P., Pélissier-Alicot, A.-L. and Fabresse, N. (2025). L'analyse des drogues comme outil de réduction des risques : méthodes, enjeux et perspectives [Drug checking in the context of harm reduction: Methods, issues and prospects] (with English abstract). Toxicologie Analytique et Clinique 37 (3) 270-280, 10.1016/j.toxac.2025.01.094.

Pelloux, A.-S., Kabaou, P., Levy-Weill, É. and Godest, P. (2026). Un bébé à l'épreuve des addictions de ses parents. Un narratif qui s'écrit sans les mots (with English abstract). Enfances et Psy (106) 127-142.

Pierantoni, E. (2025). Des SSR addictologie aux SMR conduites addictives : objectifs et enjeux d'une réforme [From SSR to SMR: The objectives and challenges of addiction rehabilitation center reform in France] (with English abstract). Psychotropes 31 (2-3) 181-197, 10.3917/psyt.312.0181.

Pitel, M., Phan, O. and Bonnaire, C. (2025). Impact of the Kusa prevention program on cannabis consumption and emotional competencies among French Polynesian adolescents. Global Health Promotion 32 (1 Suppl.) 28-37, 10.1177/17579759251317515.

Pladys, A., Fonte, D., Loyal, D., Bader, D., Stefanowski, M.L., Anwar, I. *et al.* (2025) Profiles, needs and satisfaction with healthcare among women with psychoactive substance use disorder in France: the Calliope mixed-methods study protocol. BMJ Open 15 (10) e102731, 10.1136/bmjopen-2025-102731.

Poloméni, P. and Karila, L. (2026). 40 ans d'évolution des médicaments en « addictologie ». Quelques points de repère [40 years of developments in addiction medicine: A few points of reference] (with English abstract). Psychotropes 32 (1-2) 51-68, 10.3917/psyt.321.0051.

Quintard, K. (2025). Consultation « santé de la femme » en centre d'addictologie : nouvel enjeu de santé publique (in French only). Périnatalité 17 (2) 43-50, 10.3166/rmp-2025-0240.

Redonnet, B., Eren, F., Avenin, G., Melchior, M. and Mary-Krause, M. (2025). Efficacy of cannabidiol alone or in combination with Δ-9-tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence. Addiction 120 (5) 813-834, 10.1111/add.16745.

Rolland, B. (2025). Cocaïne : gérer le syndrome de sevrage (in French only). Santé Mentale n°301 34-37.

Rolland, B. (2025). Cocaïne, la déferlante (in French only). Santé Mentale n°301 30-33.

Rolland, B., Salihi, I., Mauries, S., Medigue, I., Catoire, S., Peter-Derex, L. *et al.* (2026) Therapeutic prospects of bright light therapy in addictive disorders: a scoping review. J Neural Transm in press, 10.1007/s00702-026-03131-1.

Roose, V., André, S., Jauffret-Roustide, M. and Groupe d'étude Rebuilding Evidence on Drug Rooms (Rev-Droom) (2025). Vingt ans de discours médiatiques autour des salles de consommation à moindre risque : analyse textométrique de la presse francophone belge [Twenty years of media coverage of drug consumption rooms: A discourse analysis of the Belgian French-speaking press (2002-2023)] (with English abstract). Déviance et Société 49 (1) 39-72, 10.3917/ds.491a.0039.

Sagaon-Teyssier, L., Hoyer, M., Donadille, C., Sow, A., Assoumou, L., Ghosn, J. *et al.* (2025) Differences between men who have sex with men that use drugs and engage in chemsex and those who do not engage in chemsex in the French ANRS-PREVENIR cohort: the need to rethink harm reduction services. Substance Abuse Treatment, Prevention, and Policy 20 33, 10.1186/s13011-025-00661-x.

Saibene, A.M., Nitro, L., Carsuzaa, F., Alexandru, M., Bedarida, V., Di Bari, M. *et al.* (2025) Comprehensive Management of Cocaine-Induced Midline Destructive Lesions: A Young-IfOS Consensus. J Pers Med 15 (6), 10.3390/jpm15060231.

Santos, M.D., Briand-Madrid, L., Lévy, J., Meddeb, J.E. and Roux, P. (2025) Zines as artistic tools in harm reduction: bridging subjective experience and scientific knowledge. Harm Reduction Journal 22 (1) 55, 10.1186/s12954-025-01216-w.

Scali, C., Steyer, E., Dumoulin, M., Bergua, G., Le Noc, Y., Drahi, E. *et al.* (2025). Le cannabis thérapeutique : que disent les études scientifiques ? (in French only). Phytothérapie 23 (2) 53-56, 10.3166/phyto-2025-0453.

Sietins, E., Sagaon-Teyssier, L., Sow, A., Assoumou, L., Mora, M., Beniguel, L. *et al.* (2025). Trajectories of chemsex engagement across time among PrEP-using men who have sex with men: Results from the French ANRS-Prévenir cohort. International Journal of Sexual Health 37 (3) 525-546, 10.1080/19317611.2025.2511902.

Therribout, N., Romo, L., Hennequin, T., Chrétienneau, C., Davost, L., Fontaine, T. *et al.* (2026) Psychometric properties of ADHD screening and diagnostic tools in patients with severe substance use disorders. Int J Clin Health Psychol 26 (1) 100682, 10.1016/j.ijchp.2026.100682.

Thiercelin, N., Frem, Y. and Anastassiou, V. (2025). Une expérience d'hôpital de jour d'addictologie virtuel pendant la Covid-19 [A virtual addictology day hospital experience during the COVID-19 pandemic] (with English abstract). Alcoologie et Addictologie 45 (2) 31-37.

Tobias, S., Grant, C., Lysyshyn, M., Roux, P., Wood, E., Kerr, T. *et al.* (2026) Risk reduction behaviours following the detection of unexpected drugs through community drug checking: a cross-sectional study. Harm Reduction Journal 23 72, 10.1186/s12954-025-01374-x.

Trickey, A., Walker, J.G., Khue, P.M., Hong, T.T., Binh, N.T., Quillet, C. *et al.* (2025) Impact and cost-effectiveness of interventions to eliminate hepatitis C virus among people who inject drugs in Haiphong, Vietnam. International Journal of Drug Policy 143 104898, 10.1016/j.drugpo.2025.104898.

Trouiller, P., Le, S.M., Hoang Thi, G., Duong Thi, H., Khuat Thi Hai, O., Nham Thi, T.T. *et al.* (2025) Micro-costing analysis of a community-based psychiatric intervention among people who inject drugs in Haiphong, Vietnam. Frontiers in Psychiatry 16 1676340, 10.3389/fpsyt.2025.1676340.

Vanderkam, P., Alvarez, P., Alla, F., Fleury, B. and Castera, P. (2025). Impact de la visite d'un délégué de santé prévention sur la montée en compétences des médecins généralistes dans la prise en charge des troubles addictifs : analyse secondaire de l'étude VIGJIL [Impact of a preventive health delegate visit on the development of general practitioners' skills in the management of addictive disorders: secondary analysis of the VIGJIL study] (with English abstract). Alcoologie et Addictologie 45 (3) 22-32.

Vorspan, F. (2025). Cocaïne et troubles psychiatriques (in French only). Santé Mentale n°301 24-29.

Wegener, M., Rothen, S., Dan-Glauser, E., Lecomte, T., Potvin, S., Rochat, L. *et al.* (2025) Motives for cannabis use and readiness to change among users of the "Stop-cannabis" mobile app: Cluster analysis. JMIR Formative Research 9 e70849, 10.2196/70849.

(4) Supply, supply reduction and crime = 22 articles

Amrouche, L. (2025). Les nouveaux produits de synthèse au cœur du trafic de stupéfiants mondial [New synthetic products at the heart of global drug trafficking] (with English abstract). Actualités Pharmaceutiques 64 (646) 26-28, 10.1016/j.actpha.2025.03.007.

Bastien, M., Mezaache, S., Donadille, C., Briand Madrid, L., Lebrun, M., Martin, V. *et al.* (2025) Home cultivation of cannabis in a context of prohibition: Results from two online cross-sectional surveys

of people using cannabis daily in France. International Journal of Environmental Research and Public Health 22 (8) 1167, 10.3390/ijerph22081167.

de Kerluden, T. (2025). Pékin-Mexico-Washington DC : Géo-criminologie du fentanyl (in French only). Sécurité globale (41) 19-46, 10.54695/secug.251.0019.

Delpirou, A. (2025). France, cocaïne : en 2025, la « marée blanche » monte toujours... (in French only). Sécurité globale (43) 57-72, 10.54695/secug.253.0057.

Devault, D.A., Fabien, L., Gish, A., Richeval, C., Gaulier, J.-M. and Néfau, T. (2025). Synthetic cannabinoids in Mayotte over a year in time and space: an example of high-frequency evolution of market. Environmental Science and Pollution Research 32 (55) 30517-30539, 10.1007/s11356-025-37273-8.

Dubois, L., Magny, R., Labat, L., Augustin, C., Pinto, T., Truchot, J. *et al.* (2026) Implication of GHB in proactive drug facilitated crime in Paris, France. Forensic Science International 378 112734, 10.1016/j.forsciint.2025.112734.

Fortin, D., Di Beo, V., Kowalski, M., Sevigny, E.L., Grigg, J., Protopopescu, C. *et al.* (2025) Cannabis growers as gardeners: results from a survey among Italian and British small-scale growers. International Journal of Drug Policy 144 Part 3 104959, 10.1016/j.drugpo.2025.104959.

Gandilhon, M. (2024). Colombie : genèse et développement d'une superpuissance de la cocaïne (in French only). Problèmes d'Amérique latine (130) 21-42, 10.54695/pal.130.0021.

Gandilhon, M. (2025). Le commerce triangulaire du fentanyl, stade suprême de la globalisation criminelle (in French only). Sécurité globale (41) 7-17, 10.54695/secug.251.0007.

Gandilhon, M. (2026). La lutte contre le narcotrafic : nouveaux outils et enjeux (in French only). Cahiers français (451) 72-79.

Gandilhon, M. (2025). « Narco-État » : réalité ou fantasme ? Cahiers de la Sécurité et de la Justice (61) 89-95, 10.3917/csj.061.0090.

Gish, A., Peyré, A., Richeval, C., Pleignet, E., Cottereau, V., Gaulier, J.M. *et al.* (2025). Presence of a synthetic cannabinoid, MDMB-INACA, in "Chimique" in Mayotte: preliminary data on metabolism with a view to a future epidemiological study based on wastewater. Environmental Science and Pollution Research 32 (58) 31048-31057, 10.1007/s11356-025-36789-3.

Gish, A., Peyré, A., Richeval, C., Pleignet, E., Cottereau, V., Gaulier, J.M. *et al.* (2025). ADB-BUTINACA, a synthetic cannabinoid receptor agonist: overview of its presence in the "Chimique" in Mayotte. Environmental Science and Pollution Research 32 (53) 29905-29916, 10.1007/s11356-025-37270-x.

Granville, A., Grigg, J., Kowalski, M., Sevigny, E., Zobel, F. and Fortin, D. (2025) What can we learn from low-THC cannabis growers in Europe? A comparative transnational study of small-scale cannabis growers from Italy and Switzerland. International Journal of Drug Policy 144 Part 3 104505, 10.1016/j.drugpo.2024.104505.

Harmel, C., Caré, W., Laborde-Casterot, H., Liautard, M., Langrand, J. and Dufayet, L. (2025) 5F-AKB48: A synthetic cannabinoid presenting an emerging public health concern in France. International Journal of Drug Policy 145 104972, 10.1016/j.drugpo.2025.104972.

Hubrecht, J. (2026). La zone de crack (in French only). Esprit (531) 93-97, 10.3917/espri.2603.0093.

Lenton, S., Potter, G., Fortin, D., Granville, A., Grigg, J., Sevigny, E. *et al.* (2025) Growing practices and the use of potentially harmful chemical additives from a web survey of mainly small-scale cannabis growers in 18 countries. International Journal of Drug Policy 144 Part 3 104662, 10.1016/j.drugpo.2024.104662.

Meisel, J.S., Brummer, J.E., Sogaard, T.F., Potter, G.R., Grigg, J. and Jauffret-Roustide, M. (2025) Global cannabis cultivation as a gendered activity: Findings from the 2020 International Cannabis Cultivation Questionnaire. International Journal of Drug Policy 146 105039, 10.1016/j.drugpo.2025.105039.

Sevigny, E.L., Potter, G., Wilkins, C., Barratt, M.J., Sogaard, T.F., Hakkarainen, P. *et al.* (2025) Conflict and social control among cannabis growers. International Journal of Drug Policy 144 Part 3 104292, 10.1016/j.drugpo.2023.104292.

Sogaard, T.F., Brummer, J.E., Wilkins, C., Sznitman, S.R., Sevigny, E.L., Frank, V.A. *et al.* (2025) Global patterns in small-scale cannabis growers' distribution practices: Exploring the grower-distributor nexus. International Journal of Drug Policy 144 Part 3 104463, 10.1016/j.drugpo.2024.104463.

Tissot, N. and Plasse, A. (2025). Cocaïne, un raz-de-marée... caché ? [Cocaine, a hidden tidal wave?] (with English abstract). Psychotropes 31 (2-3) 73-95, 10.3917/psyt.312.0073.

Werse, B., Kamphausen, G., Sogaard, T.F., Bear, D., Audran, M., Wilkins, C. *et al.* (2025) Impact of the COVID-19 pandemic on cannabis cultivation and use in 18 countries. International Journal of Drug Policy 144 Part 3 104652, 10.1016/j.drugpo.2024.104652.

(5) Drug policy (including laws, economic issues and strategies) = 18 articles

Afsahi, K., Tinasti, K. and Mouna, K. (2025) Ecological dimensions of cannabis regulation in the Rif, Morocco. International Journal of Drug Policy 146 105045, 10.1016/j.drugpo.2025.105045.

Basset, B. and Rigaud, A. (2026). Association Addictions France: des enjeux d'hier à ceux d'aujourd'hui [Association Addictions France: Challenges from yesterday to today] (with English abstract). Psychotropes 32 (1-2) 239-247, 10.3917/psyt.321.0239.

Ben Lakhdar, C., Massin, S. and Vaillant, N. (2024). Légaliser et réglementer les marchés des drogues : De la pensée de Bertrand Lemennicier à aujourd'hui (in French only). Journal des Économistes et des Études Humaines 30 (1) 115-130, 10.1515/jeeh-2024-0007.

Ben Lakhdar, C. (2025). De plaisir à poison : conséquences socio-économiques des pratiques addictives (in French only). Cahiers français (448) 54-61.

Boulland, P. (2026). La République sous amphétamines. Militants et dirigeants politiques entre performance et surmenage, de la Libération aux années 1960 (with English abstract). Parlement[s], Revue d'histoire politique (43) 241-261, 10.3917/parl2.043.0241.

Chouvy, P.-A. (2025) Policy reform and the international future of Moroccan Cannabis production. International Journal of Drug Policy 142 104841, 10.1016/j.drugpo.2025.104841.

Fraichard, P., Justin, S. and Verduzier, T. (2026). SOS DROGUE International: naissance et évolution au coeur d'un enjeu social et politique [SOS Drogue International: Birth and evolution at the heart of a social and political issue] (with English abstract). Psychotropes 32 (1-2) 261-272, 10.3917/psyt.321.0261.

Fuertes, R. and Jauffret-Roustide, M. (2026). Le modèle portugais de décriminalisation des drogues (in French only). Esprit (531) 67-75, 10.3917/espri.2603.0067.

Jauffret-Roustide, M. (2025). Politique de régulation des drogues et des addictions : la France en miroir des autres pays (in French only). Cahiers français (448) 22-29.

Johnston, E. (2026). Restaurer la confiance dans l'action publique européenne (in French only). Esprit (531) 61-66, 10.3917/espri.2603.0061.

Lebeau, B. (2026). Vers l'avenir radieux ? Prohibition, légalisation, réduction des risques en 2025 [Toward a bright future? Prohibition, legalization, and harm reduction in 2025] (with English abstract). Psychotropes 32 (1-2) 141-157, 10.3917/psyt.321.0141.

Lhosmot-Marquet, M., Champeyrache, C., Donnadieu, H., Jouanjus, E., Khazaal, Y., Roux, P. *et al.* (2026). Cocaine use in Europe: the need for cross-sectoral collaboration between security, justice, health, and social systems. The Lancet Public Health 11 (1) e61-e68, 10.1016/S2468-2667(25)00283-X.

Marchant, A. (2026). Panorama général d'un demi-siècle de prohibition et de consommation de drogues en France, des années 1960 à aujourd'hui [An overview of half a century of drug prohibition and consumption in France, from the 1960s to the present day] (with English abstract). Psychotropes 32 (1-2) 25-50, 10.3917/psyt.321.0025.

Nguyen Thanh, V. (2025). Addictions : quelles politiques publiques de prévention ? (in French only). Cahiers français (448) 68-76.

Olivet, F. (2026). Pour ou contre la drogue, 50 ans de paradoxe français [For or against drugs: 50 years of a French paradox] (with English abstract). Psychotropes 32 (1-2) 211-222, 10.3917/psyt.321.0211.

Pechillon, E. and Renard, S. (2025). Cocaïne à l'hôpital : que dit le droit ? (in French only). Santé Mentale n°301 74-76.

Perseil, S. (2026). La culture de la drogue (in French only). Revue Médecine et Philosophie (14) 60-63.

Vandendriessche, A. (2025). Drogues et addictions : réponse pénale (in French only). Cahiers français (448) 62-67.

(6) Others

T4. Additional information

The purpose of this section is to provide additional information important to drug-related research in your country that has not been provided elsewhere.

T4.1. ***Optional****. Please describe any additional important sources of information, specific studies or information on drug-related research priorities. Where possible, please provide references and/or links.*

T.4.2. ***Optional****. Please describe any other important aspect of drug-related research that has not been covered in the specific questions above. This may be additional information, a reference to an organisation in your country that monitors national drug-related research, the availability of a bibliography of recent studies or new areas of specific importance for your country.*

T5. Sources and methodology

The purpose of this section is to collect sources and bibliography for the information provided above, including brief descriptions of studies and their methodology where appropriate.

T5.1. Please list notable sources for the information provided above.

MILDECA (2023). Interministerial strategy for mobilisation against addictive behaviours 2023-2027. Mission interministérielle de lutte contre les drogues et les conduites addictives, Paris. Available: https://www.drogues.gouv.fr/sites/default/files/2024-10/SIMCA_2023-2027_EN.pdf [accessed 24/09/2026].

Ben Lakhdar, C. and Massin, S. (2025). Taille des marchés des drogues illicites en France (2010-2023). OFDT, Paris. Available: https://www.ofdt.fr/publication/2025/taille-des-marches-des-drogues-illicites-en-france-2010-2023-2634 [accessed 13/07/2026].

INSERM (2026). Cocaïne. INSERM, Paris. Available: https://www.inserm.fr/expertise-collective/cocaine/ [accessed 24/09/2026].

MILDECA (2023). Stratégie interministérielle de mobilisation contre les conduites addictives 2023-2027 [Interministerial strategy for mobilisation against addictive behaviours 2023-2027]. Mission interministérielle de lutte contre les drogues et les conduites addictives, Paris. Available: https://www.drogues.gouv.fr/le-gouvernement-publie-la-strategie-interministerielle-de-mobilisation-contre-les-conduites [accessed 17/04/2026].